Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 10308. Отображено 100.
02-02-2012 дата публикации

Vapor deposition of metal oxides, silicates and phosphates, and silicon dioxide

Номер: US20120028478A1
Автор: Dennis Hausmann, Jill Becker, Roy G. Gordon, Seigi Suh
Принадлежит: Harvard College

Metal silicates or phosphates are deposited on a heated substrate by the reaction of vapors of alkoxysilanols or alkylphosphates along with reactive metal amides, alkyls or alkoxides. For example, vapors of tris(tert-butoxy)silanol react with vapors of tetrakis(ethylmethylamido)hafnium to deposit hafnium silicate on surfaces heated to 300° C. The product film has a very uniform stoichiometry throughout the reactor. Similarly, vapors of diisopropylphosphate react with vapors of lithium bis(ethyldimethylsilyl)amide to deposit lithium phosphate films on substrates heated to 250° C. Supplying the vapors in alternating pulses produces these same compositions with a very uniform distribution of thickness and excellent step coverage.

Подробнее
Номер записи: 1
09-02-2012 дата публикации

Polymers with Low Gel Content and Enhanced Gas-Fading

Номер: US20120035305A1
Автор: Hayder Zahalka, Jonathan S. Hill, Maurice Power, Michael E. Gelbin
Принадлежит: Individual

A polymer stabilizing composition comprising a sterically hindered phenol and a phosphite that provides low gel content and enhanced resistance to gas-fading. The stabilizer composition is particular useful for stabilizing polyethylene homopolymers and copolymers, such as linear low density polyethylenes produced from metallocene catalyst. The sterically hindered phenol is, for example, selected from the group consisting of 1,3,5-tris-(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)isocyanurate, 1,3,5-tris-(3,5-dicyclohexyl-4-hydroxybenzyl)isocyanurate, 1,3,5-tris-(3,5-di-tert-butyl-4-hydroxybenzyl)isocyanurate, 1,3,5-tris(4-t-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-Triazine-2,4,6-(1H,3H,5H)-trione, and 1,3,5-tris-(3,5-di-tert-butyl-4-hydroxybenzyl)-2,4,6-trimethylbenzene.

Подробнее
Номер записи: 2
01-03-2012 дата публикации

Dimethoate low voc formulations

Номер: US20120053151A1
Автор: Morten Pedersen
Принадлежит: Cheminova AS

Liquid dimethoate formulations comprising a solvent chosen among liquids comprised of a compound having a ethylenglycol-propylenglycol co-polymeric chain as well as mixtures thereof. These solvents diminish the use of VOC solvents while still providing storage stable formulations.

Подробнее
Номер записи: 3
15-03-2012 дата публикации

Methods for Production of Biodiesel

Номер: US20120065416A1
Автор: Alexander McCurdy, Bradley Wahlen, Lance Seefeldt, Robert Willis
Принадлежит: Utah State University USU

The present invention relates to methods useful for converting microbial lipids from an oleaginous microbial biomass into fatty acid alcohol esters, without prior extraction of the lipids from the biomass. The present invention also relates to fatty acid alcohol esters produced by the methods described herein. The fatty acid alcohol esters produced by the methods described herein may be useful as biodiesel, or a component thereof. In embodiments, the converting of microbial lipids to fatty acid alcohol esters may be accomplished by contacting an acid catalyst, an alcohol and an oleaginous microbial biomass containing microbial lipids under sufficient conditions and for a sufficient period of time for in situ transesterification reaction of at least some microbial lipids to their corresponding fatty acid alcohol ester.

Подробнее
Номер записи: 4
19-07-2012 дата публикации

Process for preparing alkyl phosphates

Номер: US20120184766A1
Автор: Jan-Gerd Hansel
Принадлежит: LANXESS DEUTSCHLAND GMBH

The present invention relates to a process for preparing tetraalkyl bisphosphates by reacting tetrachlorobisphosphates with alcohols, neutralizing the resultant hydrogen chloride with a base, and isolating the desired product from the reaction mixture by extraction.

Подробнее
Номер записи: 5
03-01-2013 дата публикации

Non-aqueous electrolyte additive for lithium secondary battery, non-aqueous electrolyte, and lithium secondary battery including the same

Номер: US20130004840A1
Автор: Jung-Yi Yu, Mi-hyun Lee, Sang-Il Han, Tae-Hyun Bae, Woo-Cheol Shin
Принадлежит: Samsung SDI Co Ltd

A non-aqueous electrolyte additive for a lithium secondary battery, a non-aqueous electrolyte for a lithium secondary battery, and a lithium secondary battery, the additive including a bidentate phosphorus compound represented by the following Chemical Formula 1.

Подробнее
Номер записи: 6
28-02-2013 дата публикации

Organophosphorus compounds, catalytic systems comprising said compounds and method of hydrocyanation using said catalytic systems

Номер: US20130053580A1
Автор: Ana Maldonado, Gad Rothenberg, Igor Mikhel, Paul Pringle, Sergio Mastroianni
Принадлежит: Rhodia Operations SAS

The present invention relates to organophosphorus compounds belonging to the phosphinite-phosphite family, catalytic systems comprising a metallic element forming a complex with said phosphinite-phosphite compounds and methods of hydrocyanation employed in the presence of said catalytic systems.

Подробнее
Номер записи: 7
04-04-2013 дата публикации

Phosphate Ester Compound of Hydroxy Acid Substituted Phenol Ester, Preparation Method and Medical Use Thereof

Номер: US20130085120A1
Автор: LIU Jin, YANG Jun, Zhang Wensheng
Принадлежит:

Phosphate ester compound of hydroxy acid substituted phenyl ester, preparation method and medical use thereof are provided. The title compound is shown in formula (I), in which Y=Cstraight carbon chain, Mand/or M=H, alkali metal ion, protonated amine or protonated amino acid. The compound has good water solubility and high stability in its aqueous solution, and it can release 2,6-diisopropylphenol rapidly under the action of enzymes in vivo, which has the effects of sedation, hypnosis and/or anesthesia. By protecting hydroxyl of 2,6-diisopropylphenol in compound of formula (I), the first-pass metabolic activity of 2,6-diisopropylphenol is reduced, so that the synthetic compound can be used for sedation, hypnosis and/or anesthesia. 2. The compound of claim 1 , wherein said straight carbon chain Y is a saturated carbon chain.3. The compound of claim 2 , wherein said straight carbon chain Y is —CH—CH— or —CH—CH—CH—.4. The compound of claim 1 , wherein at least one hydrogen atom of the straight carbon chain Y is substituted with a member of the group consisting of methyl claim 1 , ethyl claim 1 , cyclopropyl claim 1 , hydroxy claim 1 , sulfydryl claim 1 , amino or substituted amino group.6. The preparation method of claim 5 , wherein said deacidifying agent is pyridine or a tertiary amine compound including triethylamine.7. The preparation method of claim 6 , wherein said preparation method is performed in at least one organic solvent selected from the group consisting of methylene dichloride claim 6 , chloroform claim 6 , carbon tetrachloride claim 6 , chlorobenzene claim 6 , benzene claim 6 , methylbenzene claim 6 , petroleum ether claim 6 , cyclohexane claim 6 , n-hexane claim 6 , acetonitrile claim 6 , acetone claim 6 , DMF claim 6 , DMSO claim 6 , tetrahydrofuran claim 6 , diethyl ether claim 6 , triethylamine or pyridine.8. The preparation method of claim 5 , wherein Y of the corresponding diacid compound (III′) or dicarboxylic anhydride compound (III) is a ...

Подробнее
Номер записи: 8
11-04-2013 дата публикации

BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF

Номер: US20130090311A1
Автор: Freel Meyers Caren Laura, Webster Marie
Принадлежит: THE JOHNS HOPKINS UNIVERSITY

Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described. 2. The compound of claim 1 , where Ris hydrogen claim 1 , alkyl claim 1 , halogen claim 1 , aminoalkyl claim 1 , thioaryl claim 1 , or heteroalkyl.3. The compound of claim 1 , where Ris H claim 1 , halogen claim 1 , or hydroxyl.4. The compound of claim 1 , where Rand Rare H.5. The compound of claim 1 , where Rand Rare Cl.6. The compound of claim 1 , where Ris heteroaralkyl or aminoalkyl claim 1 , and Ris hydroxyl.7. The compound of claim 1 , where Ris alkyl.8. The compound of claim 1 , where Ris alkyl or aralkyl.9. The compound of claim 1 , where X is Cl.11. The compound of claim 10 , where Ror Rare hydrogen or nitro.12. The compound of claim 10 , where A is —C═C—.13. The compound of claim 10 , where Ris hydrogen claim 10 , alkyl claim 10 , halogen claim 10 , aminoalkyl claim 10 , thioaryl claim 10 , heteroaralkyl.14. The compound of claim 10 , where Ris H claim 10 , halogen claim 10 , or hydroxyl.15. The compound of claim 10 , where Rand Rare H.16. The compound of claim 10 , where Rand Rare Cl.17. The compound of claim 10 , where Ris heteroaralkyl or aminoalkyl claim 10 , and Ris hydroxyl.18. The compound of claim 10 , where Ris alkyl.19. The compound of claim 10 , where X is Cl.21. The compound of claim 20 , where Ris nitro and Ris H or R.22. The compound of claim 20 , where Ris hydrogen claim 20 , alkyl claim 20 , halogen claim 20 , aminoalkyl claim 20 , thioaryl claim 20 , heteroaralkyl.23. The compound of claim 20 , where Ris H claim 20 , halogen claim 20 , or hydroxyl.24. The compound of claim 20 , where Rand Rare H.25. The compound of claim 20 , where Rand Rare Cl.26. The compound of claim 20 , where Ris heteroaralkyl or aminoalkyl claim 20 , and Ris hydroxyl.27. The compound of claim 20 , where Ris alkyl.28. The compound of claim 20 , where A is —C═C—.29. The compound of claim 20 , where X is Cl.31. The compound of claim 30 , where Ris nitro ...

Подробнее
Номер записи: 9
11-04-2013 дата публикации

Method for producing aromatic diphosphates

Номер: US20130090490A1
Автор: Hiroki Sato, Hiroshi Tsuji, Katsuichi Ohtsuki, Kiyoharu Hirao
Принадлежит: Daihachi Chemical Industry Co Ltd

A method for producing an aromatic diphosphate comprising: Step 1 which is a step where a specific aromatic monohydroxy compound having a steric hindrance group at ortho-positions is made to react with phosphorus oxyhalide in the presence of a Lewis acid catalyst and then the unreacted phosphorus oxyhalide is removed under a reduced pressure to give a specific; and Step 2 which is a step where the reaction product obtained in the above step is made to react with a specific aromatic dihydroxy compound in an amount of 0.5 mol to 1 mol of halogen contained in the reaction product in the presence of a Lewis acid catalyst to give a specific aromatic diphosphate.

Подробнее
Номер записи: 10
18-04-2013 дата публикации

THIOETHER PRODRUG COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS

Номер: US20130096092A1
Автор: Appella Daniel, Appella Ettore, Hayashi Ryo, Inman John K., Miller Jenkins Lisa M., Wang Deyun
Принадлежит:

Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a method for inactivating a virus, a method for dissociating a metal ion from a zinc finger-containing protein, and a method for inhibiting the transmission of a virus. 2. The compound or salt of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare independently selected from hydrogen claim 1 , halogen claim 1 , CF claim 1 , optionally substituted alkyl claim 1 , optionally substituted alkoxy claim 1 , optionally substituted aryl claim 1 , NO claim 1 , optionally substituted acylamino claim 1 , optionally substituted arylamino claim 1 , optionally substituted acyl claim 1 , optionally substituted acyloxy claim 1 , or any of Rand Rtaken together claim 1 , Rand Rtaken together claim 1 , or Rand Rtaken together form a 5- or 6-membered saturated or unsaturated ring.34.-. (canceled)5. The compound or salt of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare independently selected from halogen claim 1 , CF claim 1 , optionally substituted alkyl claim 1 , optionally substituted alkoxy claim 1 , optionally substituted aryl claim 1 , NO claim 1 , optionally substituted acylamino claim 1 , optionally substituted arylamino claim 1 , optionally substituted acyl claim 1 , optionally substituted acyloxy claim 1 , or any of Rand Rtaken together claim 1 , Rand Rtaken together claim 1 , or Rand Rtaken together form a 5- or 6-membered saturated or unsaturated ring.67.-. (canceled)8. The compound or salt of claim 1 , wherein Ris selected from hydrogen claim 1 , optionally substituted acyl claim 1 , optionally substituted acyloxy claim 1 , optionally substituted alkoxyacyl claim 1 , optionally substituted aryloxyacyl claim 1 , optionally substituted alkyl claim 1 , optionally substituted aryl claim 1 , ...

Подробнее
Номер записи: 11
02-05-2013 дата публикации

4-Alkylresorcinol Derivative And External Preparation For Skin Containing The Same

Номер: US20130109878A1
Автор: Fukunishi Hirotada, Sato Kiyoshi, Suetsugu Masaru, Suzuki Rikako
Принадлежит: SHISEIDO COMPANY, LTD.

The present invention provides a compound that has a high whitening effect and is excellent in safety and stability and provides an external preparation for skin comprising the same. The compound of the present invention is a 4-alkylresorcinol derivative represented by formula (1) or a salt thereof: 2. The 4-alkylresorcinol derivative or a salt thereof according to claim 1 , wherein both Rand Rare groups represented by —P(O)(OR)(OR).3. The 4-alkylresorcinol derivative or a salt thereof according to claim 1 , wherein both Rand Rare hydrogen atoms.4. An external preparation for skin comprising one or more selected from the 4-alkylresorcinol derivatives according to and pharmacologically acceptable salts thereof.5. A skin-whitening agent claim 1 , wherein one or more selected from the 4-alkylresorcinol derivatives according to and pharmacologically acceptable salts thereof are active components.6. The 4-alkylresorcinol derivative or a salt thereof according to claim 2 , wherein both Rand Rare hydrogen atoms.7. An external preparation for skin comprising one or more selected from the 4-alkylresorcinol derivatives according to and pharmacologically acceptable salts thereof.8. A skin-whitening agent claim 6 , wherein one or more selected from the 4-alkylresorcinol derivatives according to and pharmacologically acceptable salts thereof are active components.9. An external preparation for skin comprising one or more selected from the 4-alkylresorcinol derivatives according to and pharmacologically acceptable salts thereof.10. A skin-whitening agent claim 2 , wherein one or more selected from the 4-alkylresorcinol derivatives according to and pharmacologically acceptable salts thereof are active components.11. An external preparation for skin comprising one or more selected from the 4-alkylresorcinol derivatives according to and pharmacologically acceptable salts thereof.12. A skin-whitening agent claim 3 , wherein one or more selected from the 4-alkylresorcinol derivatives ...

Подробнее
Номер записи: 12
20-06-2013 дата публикации

Method For Producing Alkoxylated Phosphoric Acid Triesters

Номер: US20130158284A1
Автор: Klug Peter, OBERHAUSER Adelgunde, SCHERL Franz-Xaver, SIMSCH Waltraud
Принадлежит: CLARIANT FINANCE (BVI) LIMITED

The invention relates to a method for producing phosphoric acid triesters of formula (I). According to said method, phosphoric acid or a phosphoric acid derivative selected from orthophosphoric acid, tetraphosphoric decaoxide and polyphosphoric acid is reacted with alkoxylated alcohols of formulae (II) R—(OA)—OH, (III) R—(OA)—OH, and (IV) R—(OA)—OH, in the molar ratio phosphoric acid or phosphoric acid derivative to alkoxylated alcohol of 1:2.5 to 1:3.3, at between 200 and 240° C. 15.-. (canceled)7. A phosphoric ester as claimed in claim 6 , which is chlorine-free.8. A phosphoric ester as claimed in claim 6 , wherein R claim 6 , Rand Rmay be alike or different and are a linear or branched claim 6 , saturated alkyl group having 8 to 22 carbon atoms.9. A phosphoric ester as claimed in claim 6 , wherein R claim 6 , Rand Rmay be alike or different and are a linear or branched claim 6 , saturated alkyl group having 12 to 18 carbon atoms.10. A phosphoric ester as claimed in claim 6 , wherein R claim 6 , Rand Rmay be alike or different and are a linear or branched claim 6 , mono- or polyunsaturated alkenyl group having 8 to 22 carbon atoms.11. A phosphoric ester as claimed in claim 6 , wherein R claim 6 , Rand Rmay be alike or different and are a linear or branched claim 6 , mono- or polyunsaturated alkenyl group having 12 to 18 carbon atoms.12. A phosphoric ester as claimed in claim 6 , wherein x claim 6 , y and z each independently of one another are a number from 25 to 120.13. A phosphoric ester as claimed in claim 6 , wherein x claim 6 , y and z each independently of one another are a number from 40 to 120.14. A phosphoric ester as claimed in claim 6 , wherein x claim 6 , y and z each independently of one another are a number from 51 to 100. The invention relates to a process for preparing phosphoric triesters from phosphoric acid or chlorine-free phosphoric acid derivatives and alkoxylated fatty alcohols.Phosphoric triesters are unobjectionable from the standpoints of ...

Подробнее
Номер записи: 13
11-07-2013 дата публикации

PESTICIDE COMPOSITION COMPRISING FOSETYL-ALUMINIUM, PROPAMOCARB-HCL AND AN INSECTICIDE ACTIVE SUBSTANCE

Номер: US20130178447A1
Автор: Hungenberg Heike, Thielert Wolfgang, VAN DEN EYNDE Koen
Принадлежит: Bayer CropScience AG

The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance. 1. A composition comprising: A1) fosetyl-Al', 'A2) propamocarb HCl', 'in an A1/A2 weight ratio ranging from 1/12 to 12/1, and, 'A) the compounds'}B) an insecticide compound selected from the group consisting of spirodiclofen, spiromesifen and spirotetramatein an A/B weight ratio ranging from 1/1,000 to 1,000/1.2. The composition according to claim 1 , wherein compound B is selected from the group consisting of spirodiclofen and spiromesifen.3. The composition according to claim 1 , wherein the A1/A2 weight ratio ranges from 1/3 to 3/1.4. The composition according to claim 1 , wherein the A1/A2 weight ratio is 1.5. The composition according to claim 1 , wherein the A/B weight ratio ranges from 1/125 to 125/1.6. The composition according to wherein the A/B weight ratio ranges from 1/25 to 25/1.7. The composition according to claim 1 , further comprising:C) a further fungicide compound in an A/B/C weight ratio ranging from 1/1,000/1,000 to 1/0.001/0.001.8. The composition according to claim 7 , wherein compound C is selected from the group consisting of benalaxyl claim 7 , benalaxyl-M claim 7 , benthiavalicarb claim 7 , carboxin claim 7 , chlorothalonil claim 7 , cyazofamid claim 7 , cymoxanil claim 7 , dimetomorph claim 7 , fluazinam claim 7 , fludioxonil claim 7 , fluoxastrobin claim 7 , fluquinconazole claim 7 , flutriafol claim 7 , hexaconazole claim 7 , hymexazol claim 7 , ipconazole claim 7 , mancozeb claim 7 , mandipropamid claim 7 , maneb claim 7 , mefenoxam claim 7 , metalaxyl claim 7 , metiram claim 7 , penconazole claim 7 , penthiopyrad ...

Подробнее
Номер записи: 14
11-07-2013 дата публикации

METHOD OF PREPARING BIPHENYL-4-YL DIPHENYL PHOSPHATE COMPOSITION

Номер: US20130178642A1
Автор: Jang Won Seok, Kim Myoung Lae, Kim Won Yeob
Принадлежит: SK INNOVATION CO., LTD.

Provided is a method of preparing a biphenyl-4-yl diphenyl phosphate composition for use as a flame retardant or a plasticizer for resin, including mixing phosphoryl chloride (POCl), 4-phenylphenol, and a catalyst, so that first dehydrochlorination occurs; and further adding phenol, so that second dehydrochlorination occurs. 2. The method of claim 1 , wherein the phosphoryl chloride is contained at a molar ratio of 1:2.7˜1:3.0 to a sum of 4-phenylphenol upon first dehydrochlorination and phenol upon second dehydrochlorination.3. The method of claim 1 , wherein a molar ratio of the 4-phenylphenol upon first dehydrochlorination to the phenol upon second dehydrochlorination is 1:1.8˜1:3.0.4. The method of claim 1 , wherein the catalyst comprises any one selected from the group consisting of anhydrous aluminum chloride claim 1 , anhydrous aluminum fluoride claim 1 , anhydrous magnesium chloride claim 1 , anhydrous magnesium fluoride claim 1 , anhydrous manganese chloride claim 1 , anhydrous manganese fluoride claim 1 , anhydrous ferrous chloride claim 1 , anhydrous ferric chloride claim 1 , anhydrous ferrous fluoride claim 1 , anhydrous ferric fluoride claim 1 , and mixtures thereof.5. The method of claim 1 , wherein the first dehydrochlorination is performed at −20˜0° C.6. The method of claim 1 , wherein the second dehydrochlorination is performed at 20˜50° C.7. The method of claim 2 , wherein a molar ratio of the 4-phenylphenol upon first dehydrochlorination to the phenol upon second dehydrochlorination is 1:1.8˜1:3.0. The present invention relates to a method of preparing a biphenyl-4-yl diphenyl phosphate (hereinafter referred to as “BDP”) composition suitable for use as a photo-sensitive material, a plasticizer, or a flame retardant for general-purpose resin.Currently, a phosphorus-based flame retardant is mainly available in lieu of a halogen-based flame retardant, and examples thereof include red phosphorus, phosphoric acid ester or phosphate, phosphonate, ...

Подробнее
Номер записи: 15
25-07-2013 дата публикации

Hydrothiolation of Unactivated Alkenes

Номер: US20130190505A1
Автор: Jimmy Wu, Markku A. Savolainen
Принадлежит: Dartmouth College

The present invention is a method for promoting hydrothiolation of an unactivated alkenes with a thiol using gallium triflate.

Подробнее
Номер записи: 16
25-07-2013 дата публикации

CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

Номер: US20130190524A1
Автор: Duarte Carolina, Koumbis Alexandros, Lehn Jean-Marie, Nicolau Claude, Pothukanuri Srinivasu
Принадлежит:

The present invention is directed to polyphosphorylated and pyrophosphate derivatives of cyclitols. More particularly, the invention relates to polyphosphorylated and pyrophosphate derivatives of inositols. The invention also relates to compositions of the polyphosphorylated and pyrophosphate derivatives of inositol and other similar, more lipophilic derivatives, and their use as allosteric effectors, cell-signaling molecule analogs, and therapeutic agents. 18.-. (canceled)9. A pyrophosphate inositol , wherein the pyrophosphate is an internal pyrophosphate and the inositol is cis-inositol , epi-inositol , allo-inositol , muco-inositol , neo-inositol , scyllo-inositol , (+) chiro-inositol , or (−) chiro-inositol , and wherein the pyrophosphate inositol is monopyrophosphate , bispyrophosphate , or trispyrophosphate , and comprises a derivatized hydroxyl selected from alkoxy (—OR) or acyloxy (—OCOR) , where R is selected from alkyl , aryl , acyl , aralkyl , alkenyl , alkynyl , heterocyclyl , polycyclyl , carbocycle , amino , acylamino , amido , alkylthio , sulfonate , alkoxyl , sulfonyl , or sulfoxido , or a salt thereof.10. The pyrophosphate inositol of claim 9 , wherein the pyrophosphate inositol is complexed with a cation to form a salt claim 9 , and wherein the cation is an alkali metal cation claim 9 , an alkaline metal cation claim 9 , an ammonium claim 9 , or an organic cation.11. A pharmaceutical composition comprising the pyrophosphate inositol of .1231.-. (canceled)32. The pyrophosphate inositol of claim 9 , wherein R is a lower alkyl.33. The pyrophosphate inositol of claim 32 , where R is methyl.34. The pyrophosphate inositol of claim 9 , wherein the inositol is scyllo-inositol.35. The pyrophosphate inositol of claim 9 , wherein the inositol is monopyrophosphate.36. The pyrophosphate inositol of claim 9 , wherein the inositol is bispyrophosphate.37. A pharmaceutical composition comprising a pyrophosphate inositol wherein the pyrophosphate is an internal ...

Подробнее
Номер записи: 17
08-08-2013 дата публикации

NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS

Номер: US20130202689A1
Автор: Sampalis Fotini
Принадлежит: NEPTUNE TECHNOLOGIES & BIORESSOURCES, INC.

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. 1120.-. (canceled)122. The method of claim 121 , wherein said composition is contained in a capsule suitable for oral administration.123. The method of claim 121 , wherein composition further comprises an additional lipid selected from monoglycerides claim 121 , triglycerides claim 121 , cholesterols and mixtures thereof.124. The method of claim 121 , wherein said composition comprises polyunsaturated fatty acids in an amount of at least 15% w/w of the total lipids.125. The method of claim 124 , wherein said polyunsaturated fatty acids are omega-3 fatty acids.126. The method of claim 121 , wherein said composition comprises phospholipids in an amount of at least 40% w/w.127. The method of claim 121 , wherein said composition further comprises astaxanthin.128. The method of claim 121 , wherein said composition is derived from an aquatic or marine source.130. The method of claim 129 , wherein said composition is contained in a capsule suitable for oral administration.131. The method of claim 129 , wherein composition further comprises an additional lipid selected from monoglycerides claim 129 , triglycerides claim 129 , cholesterols and mixtures thereof.132. The method of claim 129 , wherein said composition comprises polyunsaturated fatty acids in an amount of at least 15% w/w of the total lipids.133. The method of claim 132 , wherein said polyunsaturated fatty acids are omega-3 fatty acids.134. The method of claim 129 , wherein said composition comprises phospholipids in an amount of at least 40% w/w.135. The method of claim 129 , wherein said composition further comprises astaxanthin.136. The method of claim 129 , wherein said composition is derived from an aquatic or marine source.138. The method of claim 137 , wherein said composition is contained in a tablet or capsule ...

Подробнее
Номер записи: 18
08-08-2013 дата публикации

NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS

Номер: US20130204008A1
Автор: Artman, Gadwood Robert C., III Gerald D., Parker Timothy, Tanis Steven P., Zeller James R.
Принадлежит: Metabolic Solutions Development Company, LLC

The present invention provides novel methods for synthesizing PPARγ sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases. 3. The method of claim 2 , further comprising treating the compound of Formula 4A with a reagent comprising HONH.HCl claim 2 , HONH claim 2 , TMSNHOTMS claim 2 , (HNOH).HSO claim 2 , or any combination thereof to generate the compound of Formula 2A.5. The method of claim 4 , wherein X is a leaving group selected from —Br claim 4 , —Cl claim 4 , —I claim 4 , —OMs claim 4 , —OTs claim 4 , —OTf claim 4 , —OBs claim 4 , —ONs claim 4 , —O-tresylate claim 4 , or —OPO(OR) claim 4 , wherein each Ris independently Calkyl or two of Rtogether with the oxygen and phosphorous atoms to which they are attached form a 5-7 membered ring.10. The method of claim 9 , wherein Ris selected from a Calkyl or Calkoxy claim 9 , either of which is optionally substituted with 1-3 halo claim 9 , and Ris —H or halo.11. The method of claim 10 , wherein Ris Calkoxy optionally substituted with 1-3 halo claim 10 , and Ris —H.12. (canceled)13. The method of claim 4 , wherein X is selected from —Br and —Cl.15. The method of claim 1 , wherein the compound of Formula 2A is reduced to a compound of Formula 3A in the presence of a reagent comprising NaBH claim 1 , LiBH claim 1 , KBH claim 1 , or any combination thereof and a catalyst comprising CoCl.16. The method of claim 1 , wherein the compound of Formula 3A is converted to a compound of Formula I in the presence of an aqueous acid.17. The method of claim 16 , wherein the aqueous acid comprises aqueous HCl or aqueous HSO.24. The method of claim 23 , wherein Ris selected from a Calkyl or Calkoxy claim 23 , either of which is optionally substituted with 1-3 halo claim 23 , and Ris —H or halo.25. (canceled)26. The method of claim 24 , wherein Ris selected from methoxy claim 24 , ethoxy claim 24 , or propoxy ...

Подробнее
Номер записи: 19
15-08-2013 дата публикации

NOVEL PROCESS FOR THE PREPARATION OF (3S)-TETRAHYDROFURAN-3-YL (IS, 2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-(PHOSPHONOOXY) PROPYLCARBAMATE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

Номер: US20130211108A1
Автор: Arumalla Siva Reddy, Datta Debashish, Mulamalla Rajendra Reddy, Nadella Madhu Murthy, Prathi Siva Koteswara Rao, Rambhotla Ravathi Srinivas, Vellanki Siva Rama Prasad
Принадлежит:

The present invention relates to a novel process for the preparation of Fosamprenavir or its pharmaceutically acceptable salts thereof by using novel intermediates.

Подробнее
Номер записи: 20
12-09-2013 дата публикации

High-Purity Phospholipids

Номер: US20130237720A1
Автор: Halperin Gideon, Kovalevski-Ishai Eti
Принадлежит: Vascular Biogenics Ltd.

Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201). 1. 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201) being substantially pure.2. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine of having a HPLC purity of greater than about 90% (AUC).3. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine of having a HPLC purity of at least about 95% (AUC).4. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine of having a HPLC purity of at least about 97.8% (AUC).5. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine of having a HPLC purity from about 95% (AUC) to about 99.4% (AUC).6. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine of having a HPLC purity from about 97.8% (AUC) to about 99.4% (AUC).7. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine of claim 2 , wherein the HPLC purity is measured using an HPLC method in connection with a refractive index (RI) detector claim 2 , wherein the HPLC method involves a C18 reverse-phase stationary phase and a mobile phase claim 2 , which is methanol/acetonitrile/water/formic acid at a ratio of about 81/15/8/0.1 (v/v/v/v).8. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine of being substantially free of impurity C characterized by a HPLC relative retention time of about 1.05.9. The 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero- ...

Подробнее
Номер записи: 21
17-10-2013 дата публикации

COMPOSITIONS, THE PREPARATION AND USE THEREOF

Номер: US20130273145A1
Автор: Vail Neal
Принадлежит: KCI Licensing, Inc.

The present teachings provide new compositions comprising polycations and polycations, and the preparation and use of these new compositions. In one aspect, the new compositions are complex coacervates. The compositions described herein can have several desired properties, including, low interfacial tension in water, adjustable cohesive strength, antimicrobial activity, suitability for dissolution at or near physiological pH, biocompatiblility, and/or biodegradability. The compositions can have the ability of promoting cell attachment, cell adhesion, cell migration, cell differentiation, and/or morphogenesis. Thus, in various embodiments, the complex coacervates can be used in water-based applications, for example, in the body. 1. A composition for promoting cell interaction comprising a polycation and a polyanion , wherein at least one of the polycation and the polyanion comprises a peptide.2. (canceled)3. The composition of claim 1 , wherein the polycation comprises one or more amino groups.5. The composition of claim 1 , wherein at least one of the polycation and the polyanion comprises an engineered protein comprising a motif that promotes a cell interaction.6. (canceled)7. (canceled)8. (canceled)9. The composition of claim 5 , wherein the engineered protein comprises one or more sequences each independently selected from SEQ ID NO: 1 claim 5 , SEQ ID NO: 2 claim 5 , SEQ ID NO: 3 claim 5 , SEQ ID NO: 4 claim 5 , SEQ ID NO: 5 claim 5 , SEQ ID NO: 6 claim 5 , SEQ ID NO: 7 claim 5 , SEQ ID NO: 8 claim 5 , SEQ ID NO: 9 claim 5 , SEQ ID NO: 10 claim 5 , SEQ ID NO: 11 claim 5 , SEQ ID NO: 12 claim 5 , SEQ ID NO: 13 claim 5 , SEQ ID NO: 14. SEQ ID NO: 15 claim 5 , SEQ ID NO: 16 claim 5 , SEQ ID NO: 17 claim 5 , SEQ ID NO: 18 claim 5 , SEQ ID NO: 19 claim 5 , SEQ ID NO: 20 claim 5 , SEQ ID NO: 21 claim 5 , SEQ ID NO: 22 claim 5 , SEQ ID NO: 23 claim 5 , SEQ ID NO: 24. SEQ ID NO: 25 claim 5 , and SEQ ID NO: 26.10. (canceled)11. (canceled)12. The composition of claim 1 , ...

Подробнее
Номер записи: 22
07-11-2013 дата публикации

PHOSPHORUS-CONTAINING OLIGOMER AND METHOD FOR PRODUCING THE SAME, CURABLE RESIN COMPOSITION AND CURED PRODUCT OF THE SAME, AND PRINTED WIRING BOARD

Номер: US20130296597A1
Автор: Hayashi Koji, Satou Yutaka
Принадлежит:

A phosphorus-containing oligomer is represented by formula (1): 13-. (canceled)57-. (canceled) The present invention relates to a phosphorus containing oligomer that has high solubility in a solvent and exhibits high flame retardancy and heat resistance in the form of a cured product thereof, a method for producing the phosphorus-containing oligomer, a curable resin composition that uses the oligomer as a curing agent for epoxy resins, a cured product of the curable resin composition, and a printed wiring board that uses the curable resin composition.Epoxy resins and epoxy resin compositions containing a curing agent for epoxy resins as an essential component have excellent physical properties such as high heat resistance and moisture resistance and hence are widely used for, for example, semiconductor sealing materials, electronic components such as printed circuit boards, the electronic component field, conductive adhesives such as conductive pastes, other adhesives, matrices for composite materials, coating materials, photoresist materials, and development materials.In recent years, further enhancement of properties such as heat resistance, moisture resistance, and solder resistance has been demanded in such various applications, in particular, applications to advanced materials. In vehicle-mounted electronic devices that are particularly required to have high reliability, the installation position has been changed from a cabin to an engine compartment having a higher temperature than a cabin. In addition, reflowing treatment temperature has increased due to use of lead-free solder. Therefore, high heat resistant materials that have higher glass transition temperature and can endure a thermal delamination test (hereinafter, abbreviated as “T288 test”) have been demanded.When epoxy resin compositions are used as materials for printed wiring boards, a flame retardant containing halogen such as bromine is added together with an antimony compound to impart flame ...

Подробнее
Номер записи: 23
28-11-2013 дата публикации

Composition containing a polyorganosiloxane, a larvicide, and an organic solvent

Номер: US20130316984A1
Автор: AUSTIN James W., Klein Clark D., Mueller Helmut, Stutz Susanne, Taranta Claude, Weinmueller Egon
Принадлежит: BASF SE

The present invention relates to a liquid composition containing a polyorganosiloxane, a larvicide, which contains temephos, spinozad, dinetofuran, methopren, , or , and at least 10 wt % of a water-immiscible synthetic organic solvent. It also relates to a method for preparing said composition comprising mixing the polyorganosiloxane, the larvicide, and optionally the further components; and to a method for controlling insects, wherein the said composition is applied on a water surface. 116-. (canceled)17. A method for controlling insects comprising the application of a liquid composition on a water surface , wherein the composition containsa polyorganosiloxane;{'i': Bacillus thuringiensis, Bacillus thuringiensis israelensis', 'Bacillus sphaericus, 'a larvicide, which contains temephos, spinozad, dinetofuran, methopren, , or ; and'}{'sub': 5', '12', '5', '18', '6', '24', '1', '6', '2', '18, 'at least 10 wt % of a water-immiscible synthetic organic solvent, wherein the synthetic organic solvent comprises an aliphatic C-Cketone, C-Caliphatic hydrocarbon, ester of aliphatic C-Calcohol with aliphatic C-Cacid, and/or an aliphatic di-C-Cether.'}18. The method according to claim 17 , wherein the insects are aquatic insects.19. The method according to claim 17 , wherein the water surface is that of a lake claim 17 , river claim 17 , sea claim 17 , swamp claim 17 , rice field claim 17 , roadside ditch claim 17 , swimming pool claim 17 , salt marsh claim 17 , or water barrel.20. The method according to claim 17 , wherein the composition is applied with dose rate of 0.1 to 5 l/ha.21. The method according to claim 17 , wherein the composition contains up to 5 wt % water.22. The method according to claim 17 , wherein the larvicide is temephos.23. The method according to claim 17 , wherein the synthetic organic solvent comprises a mixture of synthetic organic solvents.24. The method according to claim 17 , wherein the polysiloxane comprises polydimethylsiloxane.25. The method ...

Подробнее
Номер записи: 24
28-11-2013 дата публикации

Nickel compositions for preparing nickel metal and nickel complexes

Номер: US20130317242A1
Автор: John J. Ostermaier
Принадлежит: Invista North America LLC

Nickel(II) compositions for use in manufacturing nickel metal (Ni(0)) compositions, and specifically to methods of making basic nickel carbonates used to produce nickel metal compositions are disclosed. By varying the molar ratios of carbonates and bicarbonates to nickel salts, the methods provide basic nickel carbonates that produce superior nickel metal-containing solids that are well-suited to forming nickel-ligand complexes with phosphorus-containing ligands. The phosphorus-containing ligands can be monodentate or bidentate phosphorus-containing ligands.

Подробнее
Номер записи: 25
28-11-2013 дата публикации

METHOD FOR THE PURIFICATION OF BIPHEPHOS

Номер: US20130317246A1
Автор: Christiansen Andrea, Fridag Dirk, Kreidler Burkard, Neumann Doris, Schemmer Bernhard, Wechsler Bjoern
Принадлежит: Evonik Oxeno GmbH

The invention relates to a process for the purification of 6,6′-[(3,3′-di-tert-butyl-5,5′-dimethoxy-1,1′-biphenyl-2,2′diyl)bis(oxy)]bis(dibenzo[d,f][1,3,2]dioxaphosphepin), abbreviation: biphephos (see formula 1). 1. A process for purifying biphephos , the process comprising:washing out the biphephos with at least one solvent selected from the group consisting of ethyl acetate, anisole, ortho-xylene, toluene, acetone, 2-propanol and C5-C10-alkane,recrystallizing the biphephos from the solvent, or both.2. The process according to claim 1 , wherein the solvent is acetonitrile-free.3. The process according to claim 1 , further comprising removing acetonitrile from the solvent.4. The process according to claim 1 , further comprising:dissolving the biphephos in the solvent,removing insoluble constituents by filtration,precipitating out or crystallizing out the biphephos, and by cooling the solventoptionally precipitating out or crystallizing out further biphephos by adding a C5-C10-alkane.5. The process according to claim 4 , wherein the solvent has a temperature of more than 50° C. and the insoluble constituents are removed by hot filtration.6. The process according to claim 1 , wherein the biphephos before the recrystallizing has a total chlorine content of up to 5000 ppm and after the recrystallizing has a total chlorine content of less than 500 ppm.7. The process according to claim 1 , comprising recrystallizing the biphephos from the solvent claim 1 ,wherein the solvent comprises up to 20% by weight of n-heptane and at least 50% by weight of ortho-xylene.8. The process according to claim 1 , comprising recrystallizing the biphephos from the solvent claim 1 ,wherein the solvent comprises up to 10% by weight of n-heptane and at least 90% by weight of ethyl acetate.9. The process according to claim 1 , further comprising claim 1 , after the recrystallizing claim 1 , isolating the biphephos claim 1 , and claim 1 , optionally claim 1 , drying the biphephos.10. (canceled) ...

Подробнее
Номер записи: 26
26-12-2013 дата публикации

Process for preparing malathion for pharmaceutical use

Номер: US20130345463A1
Автор: Daniella Gutman, Wael Baidussi
Принадлежит: Taro Pharmaceuticals North America Inc

The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.

Подробнее
Номер записи: 27
16-01-2014 дата публикации

PHOSPHOROUS-CONTAINING FLAME RETARDANTS FOR POLYURETHANE FOAMS

Номер: US20140018509A1
Автор: Qi Yu Dong, Tai Xiang Yang
Принадлежит: Dow Global Technologies, LLC

Embodiments of the invention include a phosphorus containing flame retardant which may be the reaction product of a reaction mixture where the reaction mixture includes at least one first polyol and at least one phosphorus containing compound having the general formula (1), (2) or combination thereof: 3. The phosphorus containing flame retardant of claim 1 , wherein R is at least one of propylene claim 1 , 2-methylpropylene claim 1 , neopentylene claim 1 , and 2-butyl-2-ethylpropylene.4. The phosphonate flame retardant of claim 1 , wherein X is selected from the group consisting of Cl claim 1 , Br claim 1 , and I claim 1 , and sulfonate.5. The phosphorus containing flame retardant of claim 1 , wherein the phosphorus containing compound is 2-Chloro-5 claim 1 ,5-dimethyl-1 claim 1 ,3 claim 1 ,2-dioxaphosphinane.6. The phosphorus containing flame retardant of claim 1 , wherein the at least one first polyol comprises at least one of polyoxalkylene polyol having an equivalent weight about 50-2500 and a combined nominal functionality of about 2-10.7. The phosphorus containing flame retardant of claim 6 , wherein the at least one polyoxalkylene polyol is initiated with glycerol claim 6 , sucrose claim 6 , sorbitol claim 6 , or a combination thereof claim 6 , and the polyoxalkylene comprises at least one of polyoxyethylene and polyoxypropylene.8. The phosphorus containing flame retardant of claim 1 , wherein the first polyol comprises a sorbitol initiated polyoxypropylene polyol with an equivalent weight of between about 100 and about 200.9. The phosphorus containing flame retardant of claim 1 , wherein the first polyol comprises a polyoxyethylene polyoxypropylene polyol initiated with a blend of glycerol and sucrose and having an equivalent weight of between about 1 claim 1 ,000 and about 2500 and a polyoxyethylene percentage of between about 15% and about 40% claim 1 , based on the weight of the polyoxyethylene polyoxypropylene polyol.10. The phosphorus containing flame ...

Подробнее
Номер записи: 28
13-02-2014 дата публикации

INOSITOL HEXAKISPHOSPHATE ANALOGS AND USES THEREOF

Номер: US20140045799A1
Автор: Braun Werner, Nauduri Dhananjaya, Oezguen Numan, Savidge Tor C., Schein Catherine, Urvil Petril
Принадлежит: The Board of Regents of the University of Texas System

Provided herein are analog and derivative compounds of inositol hexakisphosphate effective to treat a infection and to neutralize the bacterial toxins produced by the same. In addition, methods of treating the infection and for neutralizing its toxins with the compounds are provided. 120.-. (canceled)22Clostridium difficile. The method of claim 21 , wherein the bacterial toxin is TcdA claim 21 , TcdB claim 21 , or TcdA and TcdB.23C. difficileClostridium difficile. The method of claim 21 , wherein the bacterial toxin is in a subject having a infection.24. The method of claim 23 , wherein the analog is administered orally to the subject.25. (canceled)26. The method of claim 21 , wherein Rand one of R claim 21 , R claim 21 , R claim 21 , or Rare —PS(OH).27. The method of claim 21 , wherein R claim 21 , R claim 21 , and one of R claim 21 , R claim 21 , R claim 21 , or Rare —PS(OH).28. The method of claim 21 , wherein R claim 21 , R claim 21 , and one of R claim 21 , R claim 21 , R claim 21 , or Rare —PS(OH).29. The method of claim 21 , wherein R claim 21 , R claim 21 , and one of R claim 21 , R claim 21 , R claim 21 , or Ris —PS(OH).30. The method of claim 21 , wherein R claim 21 , Rand one of R claim 21 , R claim 21 , R claim 21 , or Rare —PS(OH).31. The method of claim 21 , wherein R claim 21 , R claim 21 , R claim 21 , R claim 21 , R claim 21 , and Rare —PS(OH).32. The method of claim 31 , wherein the inositol analog is a myo-inositol analog.33. The method of claim 21 , wherein Rand one of R claim 21 , R claim 21 , R claim 21 , or Rare —PSe(OH).34. The method of claim 21 , wherein R claim 21 , R claim 21 , and one of R claim 21 , R claim 21 , R claim 21 , or Rare —PSe(OH).35. The method of claim 21 , wherein R claim 21 , R claim 21 , and one of R claim 21 , R claim 21 , R claim 21 , or Rare —PSe(OH).36. The method of claim 21 , wherein R claim 21 , R claim 21 , and one of R claim 21 , R claim 21 , R claim 21 , or Ris —PSe(OH).37. The method of claim 21 , wherein R ...

Подробнее
Номер записи: 29
27-03-2014 дата публикации

USE OF LONG CHAIN POLYUNSATURATED FATTY ACID DERIVATIVES TO TREAT SICKLE CELL DISEASE

Номер: US20140088047A1
Автор: Hoem Nils, Vadas Elizabeth B.
Принадлежит: AKER BIOASSIST AS

The present invention relates to the use of long chain polyunsaturated fatty acids to treat diseases associated with red blood cells and cell membranes, and in particular to the use of derivatives of long chain fatty acids to treat sickle cell disease. 2. Method of claim 1 , wherein said composition comprises at least 30% long chain polyunsaturated fatty acid moieties on a w/w basis.3. Method of claim 1 , wherein said composition comprises at least 40% long chain polyunsaturated fatty acid moieties on a w/w basis.4. Method of claim 1 , wherein said composition comprises at least 60% long chain polyunsaturated fatty acid moieties on a w/w basis.5. Method of claim 1 , wherein said composition comprises at least 80% long chain polyunsaturated fatty acid moieties on a w/w basis.6. Method of claim 1 , wherein said long chain fatty acid moieties are selected from the group consisting of eicosapentaenoic acid claim 1 , docosahexaenoic acid claim 1 , and combinations thereof.7. Method of claim 1 , wherein said composition comprises at least 40% w/w of said phospholipid compounds.8. Method of claim 1 , wherein said composition comprises at least 60% w/w of said phospholipid compounds.9. Method of claim 1 , wherein said composition comprises at least 80% w/w of said phospholipid compounds.10. Method of claim 7 , wherein said composition comprises a mixture of said phospholipid compounds claim 7 , said mixture comprising at least 20% w/w long chain polyunsaturated fatty acid moieties.11. Method of claim 7 , wherein said composition comprises a mixture of said phospholipid compounds claim 7 , said mixture comprising at least 30% w/w long chain polyunsaturated fatty acid moieties.12. Method of claim 7 , wherein said composition comprises a mixture of said phospholipid compounds claim 7 , said mixture comprising at least 50% w/w long chain polyunsaturated fatty acid moieties.13. Method of claim 10 , wherein said long chain polyunsaturated fatty acid moieties are selected from the ...

Подробнее
Номер записи: 30
10-04-2014 дата публикации

ENZYME INHIBITING COMPOUNDS AND METHODS

Номер: US20140100198A1
Автор: Oldfield Eric, Wang Ke, Wang Weixue, Zhang Yonghui
Принадлежит: The Board of Trustees of the University of Illinois

The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an FeScluster of an isoprenoid biosynthesis enzyme. 4. The method of wherein the compound of Formula I is agrocybin claim 1 , alfaprostol claim 1 , azafenidin claim 1 , barban claim 1 , beraprost claim 1 , carfimate claim 1 , cicutoxin claim 1 , clodinafop-propargyl claim 1 , danazol claim 1 , desogestrel claim 1 , dimethisterone claim 1 , efavirenz claim 1 , enanthotoxin claim 1 , eniluracil claim 1 , ethchlorvynol claim 1 , ethinamate claim 1 , ethinyl estradiol claim 1 , ethisterone claim 1 , ethynodiol diacetate claim 1 , etonogestrel claim 1 , flumioxazin claim 1 , gephyrotoxin claim 1 , gestodene claim 1 , gestrinone claim 1 , haloprogin claim 1 , helenynolic acid claim 1 , hexapropymate claim 1 , histrionicotoxin claim 1 , iloprost claim 1 , lynestrenol claim 1 , mepanipyrim claim 1 , meparfynol claim 1 , mestranol claim 1 , methohexital sodium claim 1 , 2-methyl-3-butyn-2-ol claim 1 , mifepristone claim 1 , moxestrol claim 1 , o-nitrophenylpropiolic acid claim 1 , norethindrone claim 1 , norethynodrel claim 1 , norgestimate claim 1 , norgestrel claim 1 , norgestrienone claim 1 , oxadiargyl claim 1 , oxenin claim 1 , oxotremorine claim 1 , oxybutynin claim 1 , pargyline claim 1 , parsalmide claim 1 , 1-pentol (3-methyl-2-penten-4-yn-1-ol) claim 1 , phthalofyne claim 1 , pinazepam claim 1 , prallethrin claim 1 , propargite claim 1 , propyzamide claim 1 , ...

Подробнее
Номер записи: 31
07-01-2016 дата публикации

METHOD FOR CONTROLLING PHYTOPATHOGENIC FILAMENTOUS FUNGI OTHER THAN OOMYCETE MICROORGANISMS

Номер: US20160000083A1
Автор: FUKUYO Akie, Kato Kazushige, SAIGA Tomoyuki, Watanabe Shinya
Принадлежит:

Phytopathogenic filamentous fungi other than oomycete microorganisms are controlled using at least one compound selected from among tetrazoyloxime derivatives represented by formula (I) and salts thereof 2RhizopusFusarium.. The method according to claim 1 , wherein the phytopathogenic filamentous fungi other than oomycete microorganisms belong to genus or genus The present invention relates to a method for controlling phytopathogenic filamentous fungi other than oomycete microorganisms. More specifically, the present invention relates to a method for controlling phytopathogenic filamentous fungi other than oomycete microorganisms with superior efficacy using a low concentration of an active ingredient.Priority is claimed on Japanese Patent Application No. 2013-042625, filed Mar. 5, 2013, the content of which is incorporated herein by reference.Patent Document 1 discloses that a tetrazoyloxime derivative and agricultural chemicals containing the tetrazoyloxime derivative as an active ingredient exhibit a particularly powerful effect in the prevention and treatment of plant diseases caused by fungi of the genus Pythium including Pythium ultimum, the genus Aphanomyces, or oomycetes belonging to closely related genera.Further, Patent Document 2 discloses that a tetrazoyloxime derivative and agricultural chemicals containing the tetrazoyloxime derivative as an active ingredient exhibit effectiveness against plant diseases caused by various filamentous fungi including oomycetes, zygomycetes, ascomycetes, basidiomycetes and deuteromycetes. The publication specifically mentions powerful effects upon the oomycetes Plasmopara viticola and Phytophthora infestans.Patent Document 1: JP 2009-269913 APatent Document 2: WO 03/016303Incidentally, symptoms similar to the damage caused to rice plants by damping-off fungi can also be caused by phytopathogenic filamentous fungi belonging to the genus or the genus . However, minimal investigation has been conducted relating to effective ...

Подробнее
Номер записи: 32
05-01-2017 дата публикации

ANTIMICROBIAL COMPOSITION INCLUDING PHYTIC ACID AND ELECTROLYTES

Номер: US20170000134A1
Автор: Kim Nam-Hee, Rhee Min-Suk
Принадлежит:

The present invention relates to an antimicrobial composition including phytic acid and electrolytes. 15-. (canceled)6. A disinfection method comprising treating food poisoning bacteria with an antimicrobial composition comprising phytic acid and one or more electrolytes selected from the group consisting of sodium chloride , potassium chloride , calcium chloride and magnesium chloride.7Campylobacter jejuni, Yersinia enterocolitica, CronobacterShigellaVibrioEscherichia coliSalmonella Typhimurium, Clostridium perfringens, Clostridium botulinum, BacillusStaphylococcus aureusListeria monocytogenes.. The disinfection method of claim 6 , wherein the food poisoning bacteria is one or more among spp. claim 6 , spp. claim 6 , spp. claim 6 , 0157:H7 claim 6 , spp. claim 6 , claim 6 , and8. The disinfection method of claim 6 , wherein the antimicrobial composition comprises claim 6 , with respect to a total mass of the composition claim 6 , 0.2% to 5.0% by mass of the phytic acid and 1.0% to 5.0% by mass of the electrolyte. This application claims priority to Korean Application No. 10-2015-0094098 filed on Jul. 1, 2015 and Korean Application No. 10-2015-0147975 filed on Oct. 23, 2015, which applications are incorporated herein by reference.The present invention relates to an antimicrobial composition including phytic acid and electrolytes.Inositol hexaphosphoric acid, a main component of phytic acid, is a light yellow- or brown-colored syrup state liquid, and is known to be odourless. Structurally, inositol hexaphosphoric acid is a material having inositol as a basic structural body bonding to 6 phosphoric acid (HPO) with 12 hydroxyl groups, and thereby having a relatively high molecular weight of 660.03 g/mol.Phytic acid performs a role of a phosphoric acid storehouse in most plant bodies, and is widely distributed in various plant bodies such as beans, tree fruits and grain hulls. Accordingly, phytic acid may be separated and purified using a waste such as hulls and skins ...

Подробнее
Номер записи: 33
06-01-2022 дата публикации

METHOD FOR THE PREPARATION OF LYSOPHOSPHATIDYLINOSITOL

Номер: US20220002325A1
Автор: Huang Shengshi, Li Songying, LI Zheng
Принадлежит:

The present invention relates to a high-LPI lysolecithin and methods related to the same. The high-LPI product is produced through the reaction of lecithin with a unique method using solvent, buffer/water, and phospholipase. Using the current production method, LPI content increased from 1.4% to 3.2-13.1% using regular soy lecithin as the starting material and LPC, LPE and LPA contents also increased from 5.1%, 2.0%, 1.0% to 15.8%, 14.6% and 4.4% respectively. 1. A method of producing high-LPI lysolecithin wherein the resulting lysolecithin comprises at least 2.5% by weight LPI.2. The method of comprising the steps of:combining the source of lecithin with at least one organic solvent; and a phospholipase to form a mixture.3. The method of further including the step of further combining the source of lecithin with at least one buffer or water to form the mixture.4. The method of wherein the organic solvent is an acetate or an ether.5. The method of wherein the organic solvent is selected from the group consisting of ethyl acetate (EtOAc) claim 2 , methyl tert-butyl ether and isopropyl acetate (iPrOAc).6. The method of wherein the phospholipase is phospholipase A1 (PLA1).7. The method of wherein the buffer is a phosphate buffer.8. The method of wherein the phosphate buffer is phosphate buffered solution (PBS).9. The method of wherein the organic solvent is included in an amount of at least about 100% volume of organic solvent to lecithin weight.10. The method of wherein the organic solvent is included in an amount of between 300-600% volume of solvent to lecithin weight.11. The method of wherein the buffer or water is included in an amount of at least about 1% by weight buffer or water to lecithin weight.12. The method of wherein the buffer or water is included in an amount of about 20-90% weight of buffer or water to lecithin weight being preferred.13. The method of wherein the PLA1 is included in an amount of at least about 0.1% by weight PLA1 to lecithin weight.14. ...

Подробнее
Номер записи: 34
06-01-2022 дата публикации

CATALYZED AND GREEN PROCESS OF MALATHION

Номер: US20220002326A1
Автор: Fan Bolin, Huang David, Luo Kevin
Принадлежит:

The present invention relates to an improved synthesis of malathion. The presence of an acid facilitates the reaction between O,O-dimethyldithiophosphoric acid (O,O-DMDTPA) and maleate and leads to excellent product yield in shorter reaction time with fewer impurities. 1. A method of producing malathion , comprising reacting O ,O-dimethyldithiophosphoric acid (O ,O-DMDTPA) with diethyl maleate in the presence of an acid.2. The method of claim 1 , further comprising claim 1 , prior to reacting the O claim 1 ,O-dimethyldithiophosphoric acid (O claim 1 ,O-DMDTPA) with the maleate claim 1 ,(a) mixing the O,O-dimethyldithiophosphoric acid (O,O-DMDTPA) with the acid to form a mixture; and(b) adding the diethyl maleate to the mixture.3. The method of claim 2 , wherein the temperature of step (a) is controlled at between about 5 and about 20° C.4. The method of claim 2 , wherein the temperature of step (b) is controlled at between about 10 and about 25° C.5. The method of claim 2 , wherein the temperature is controlled at between about 20 and about 50° C. after completing the addition of the diethyl maleate to the mixture.6. The method of claim 2 , wherein the temperature is controlled at between about 35 and about 45° C. after completing the addition of the diethyl maleate to the mixture.7. The method of claim 1 , wherein the acid ranges from about 0.1% to about 20% in the mixture of step (a) by weight.8. The method of claim 1 , wherein the acid ranges from about 1% to about 10% in the mixture of step (a) by weight.9. The method of claim 1 , wherein the acid is hydrochloric acid or sulfuric acid.10. The method of claim 1 , wherein the acid is hydrochloric acid having a concentration ranging from about 20% to about 37% by weight claim 1 , or sulfuric acid having a concentration ranging from about 70% to about 98% by weight.11. The method of claim 1 , wherein the acid consists essentially of saturated hydrochloric acid.12. The method of claim 1 , wherein the molar ratio ...

Подробнее
Номер записи: 35
05-01-2017 дата публикации

COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY

Номер: US20170001950A1
Автор: Ahmadian Mohammad, Akopian Violetta, Gaudette John A., Hou Zheng, Knopov Victor, Niitsu Yoshiro, Payne Joseph E., Perelman Loren A., Tanaka Yasunobu, Witte Richard P.
Принадлежит:

Here described are compounds consisting of the structure 1. A compound , consisting of the structure (retinoid)-linker-(retinoid) , wherein m and n are independently 1 , 2 , or 3; wherein m+n=4-6; and wherein the linker comprises one or more elements selected from a polyethylene glycol (PEG) , glutarate (Glu) , hexyl , Gly , and 4-aminobutanoate (GluNH).2. The compound of claim 1 , wherein the retinoid is selected from vitamin A claim 1 , retinoic acid claim 1 , tretinoin claim 1 , adapalene claim 1 , 4-hydroxy(phenyl)retinamide (4-HPR) claim 1 , retinyl palmitate claim 1 , retinal claim 1 , saturated retinoic acid claim 1 , and saturated claim 1 , demethylated retinoic acid.3. (canceled)4. The compound of claim 1 , wherein the compound is selected from (retinoid)-PEG-(retinoid) claim 1 , (retinoid)-bis-amido-PEG-(retinoid) claim 1 , and (retinoid)-Lys-bis-amido-PEG-Lys-(retinoid).5. The compound of claim 4 , wherein the retinoid is selected from vitamin A claim 4 , retinoic acid claim 4 , tretinoin claim 4 , adapalene claim 4 , 4-hydroxy(phenyl)retinamide (4-HPR) claim 4 , retinyl palmitate claim 4 , retinal claim 4 , saturated retinoic acid claim 4 , and saturated claim 4 , demethylated retinoic acid.8. The compound of claim 1 , wherein the PEG is mono disperse.9. A composition comprising the compound of .10. The composition of claim 9 , further comprising a lipid molecule.11. The composition of claim 10 , consisting of a liposomal composition.12. The composition of claim 10 , wherein the compound of is at least partially exposed on the exterior of the liposomal composition.13. The composition of claim 11 , wherein the retinoid is 0.1 mol % to 20 mol % of the liposomal composition.14. The compound of claim 1 , wherein the polyethylene glycol has a molecular weight of about 550 to about 2000 g/mole.15. A compound consisting of the structure (retinoid)-linker-(retinoid) claim 1 , wherein m and n are 1 or 2; wherein m+n=3; and wherein the linker comprises one or more ...

Подробнее
Номер записи: 36
03-01-2019 дата публикации

PROCESSES FOR PRODUCING ORGANOPHOSPHOROUS COMPOUNDS

Номер: US20190002485A1
Автор: Bigi Marinus A., Brammer Michael A., Miller Glenn A.
Принадлежит: DOW TECHNOLOGY INVESTMENTS LLC

The present invention relates to processes for producing organophosporous compositions having low acid content as well as processes for reprocessing partially degraded organophosporous compositions that contain high levels of phosphorous acid. In one embodiment, a process comprises: (a) receiving a solid organophosphite compound that has been recrystallized or triturated, wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in a an aromatic hydrocarbon solvent in the absence of water and free amine, wherein the hydrocarbon solvent comprises an aromatic hydrocarbon, a saturated aliphatic hydrocarbon, or a mixture thereof; and (c) removing undissolved phosphorous acid from the solution, wherein the acid content of the organophosphite following step (c) is 30 ppm or less. 1. A process comprising: (a) receiving a solid organophosphite compound that has been recrystallized or triturated , wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in a hydrocarbon solvent , wherein the hydrocarbon solvent comprises an aromatic hydrocarbon , a saturated aliphatic hydrocarbon , or a mixture thereof; and (c) removing undissolved phosphorous acid from the solution , wherein the acid content of the organophosphite following step (c) is 30 ppm or less.2. The process of claim 1 , wherein the undissolved phosphorous acid is removed by filtration.3. The process of claim 1 , wherein the undissolved phosphorous acid is removed by centrifugation.4. The process of claim 1 , wherein the acid content of the organophosphite following step (c) is 10 ppm or less.5. The process of claim 1 , wherein the acid content of the organophosphite following step(c) is 5 ppm or less.6. The process of claim 1 , further comprising (d) concentrating the organophosphite in hydrocarbon solution; (e) combining the concentrated organophosphite in hydrocarbon solution with an anti- ...

Подробнее
Номер записи: 37
03-01-2019 дата публикации

PROCESSES FOR PRODUCING ORGANOPHOSPHOROUS COMPOUNDS

Номер: US20190002486A1
Автор: Bigi Marinus A., Brammer Michael A., Miller Glenn A.
Принадлежит: DOW TECHNOLOGY INVESTMENTS LLC

The present invention relates to processes for producing organophosporous compositions having low acid content as well as processes for reprocessing partially degraded organophosporous compositions that contain high levels of phosphorous acid. In one embodiment, a process comprises: (a) receiving a solid organophosphite compound that has been recrystallized or triturated, wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in an organic solvent; (c) treating the solution with a weakly basic adsorbent; and (d) collecting the treated organophosphite solution, wherein the acid content of the organophosphite following step (d) is 30 ppm or less. 1. A process comprising: (a) receiving a solid organophosphite compound that has been recrystallized or triturated , wherein the solid organophosphite compound comprises phosphorous acid; (b) dissolving the solid organophosphite compound in an organic solvent; and (c) treating the solution with a weakly basic adsorbent; and (d) collecting the treated organophosphite solution , wherein the acid content of the organophosphite following step (d) is 30 ppm or less.2. The process of claim 1 , wherein the weakly basic adsorbent comprises a metal oxide claim 1 , a metal carbonate claim 1 , or an anionic clay having an effective pKa of less than 12 or a weakly basic ion exchange resin.3. The process of claim 2 , wherein the weakly basic adsorbent comprises a weakly basic ion exchange resin claim 2 , and the weakly basic ion exchange resin comprises at least 10 equivalents of a basic moiety per mole of acid in the organophosphite solution.4. The process of claim 1 , wherein the solid organophosphite compound is dissolved in the organic solvent in the absence of free amine.5. The process of claim 1 , wherein the solvent comprises toluene claim 1 , xylenes claim 1 , diethyl ether claim 1 , dichloromethane claim 1 , ethyl acetate claim 1 , butyraldehyde claim 1 , ...

Подробнее
Номер записи: 38
20-01-2022 дата публикации

SELECTIVE DETECTION OF BED BUGS

Номер: US20220017551A1
Автор: Beach Mark W., Giampietro Natalie C., Shankar Ravi, Spomer Neil A.
Принадлежит:

A device, system, and method of controlling pests are disclosed. A pest control device includes a sensor having a sensor cell and a controller. A surface of the sensor cell is coated with an agent that reacts with a targeted biochemical analyte secreted by pests. The controller is coupled to the sensor and is configured to receive sensor data from the sensor cell indicative of a rate of change in sensor mass detected on the surface of the sensor cell, determine whether the rate of change in the sensor mass based on the received sensor data exceeds a predefined threshold rate, and transmit a pest detection alert notification to a server in response to a determination that the rate of change exceeds the predetermined threshold rate. 1115-. (canceled)117. The thiol of wherein each of Rand Ris C-Calkylene-O—(C-Calkylene)R.118. The thiol of wherein each of Rand Ris C-Calkylene-O—(C-Calkylene)Rand wherein q is zero.119. The thiol of wherein each of Rand Ris C-Calkylene-O—(C-Calkylene)R claim 116 , wherein q is zero claim 116 , and wherein Ris C-Calkyl. The present application claims the benefit of U.S. Provisional Patent Application No. 62/770,413, filed on Nov. 21, 2018, the disclosure of which is incorporated herein by reference.Cross reference is made to U.S. application Ser. No. 15/985,093, filed May 21, 2018, and International Application Serial No. PCT/US2018/033679, filed May 21, 2018.The present disclosure relates generally to pest control, and more particularly, to the detection, monitoring, and control of insects, including for example, bed bugs.Recent data suggests bed bug infestations (species) of human domiciles are on the rise. At least 92 species have been identified globally, of which at least 16 species are in the North American continent. Generally, bed bugs are parasitic pests with hosts including humans and various domesticated animals. It is believed that bed bug infestations are becoming more problematic now at least in part because long acting, ...

Подробнее
Номер записи: 39
12-01-2017 дата публикации

CARBONATE PRODRUGS AND METHODS OF USING THE SAME

Номер: US20170008916A1
Автор: Bley Keith R., Muhammad Naweed
Принадлежит:

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages. 132-. (canceled) This application claims priority benefit of U.S. Provisional Application No. 61/054.765, entitled “Carbonate Prodrugs and Methods of Using The Same” filed May 20, 2008, the content of which is hereby incorporated by reference in its entirety as if it was set forth in full below.A drug which exhibits an excellent bioactivity and safety profile when tested in experimental models may be less active and/or more toxic when administered to human subjects. One possible reason for this disparity is that a molecule may be unable to reach target site(s) of action at therapeutic concentrations and/or accumulate at toxic levels in one or more tissues. Such pharmacokinetic differences between in vitro and in vivo models, and between test species and huran may significantly limit the therapeutic utility of certain compounds, making drug development a challenge.Physicochemical properties, therapeutically effective dosage, and route of administration, can each influence the pharmacokinetic profile of a drug molecule. The therapeutically effective dosage is fixed for a particular drug. Nonetheless, a change in the route of administration may allow a reduced drug dosage if the new route offers higher bioavailability. For instance, given suitable physicochemical properties, a drug with poor oral bioavailability requiring a high dosage may be formulated for parenteral administration at a lower dosage due to its improved bioavailability. However, a different route of administration is generally possible only if physicochemical properties of a given ...

Подробнее
Номер записи: 40
12-01-2017 дата публикации

METHOD FOR PREPARING RACEMIC OR OPTICALLY ACTIVE alpha-GLYCEROPHOSPHORYLCHOLINE

Номер: US20170008917A1
Автор: HWANG Soon Ook, YUN Dae Myoung
Принадлежит:

A method of preparing racemic or optically active D or L-α-glycerophosphorylcholine in large amounts by subjecting choline phosphate or a salt thereof, and racemic or optically highly pure (S) or (R)-3-halo-1,2-propanediol to a substitution reaction in a medium at high temperature in the presence of an inorganic base which increases the activity of the reaction. The method is cost-effective because of the use of starting materials which are inexpensive compared to those in a conventional method. Moreover, the method is simple and convenient because it is performed via a one-pot reaction without a separate purification process. In addition, it enables a large amount of racemic or optically active D or L-α-glycerophosphorylcholine, or a salt thereof, to be quantitatively produced in a medium without side reactions by using the inorganic base which increases the reaction activity. 21. The method of , wherein an inorganic base is additionally used in the substitution reaction to increase activity of the reaction.3. The method of claim 2 , wherein the inorganic base is selected from the group consisting of sodium hydroxide claim 2 , potassium hydroxide claim 2 , calcium hydroxide claim 2 , magnesium hydroxide claim 2 , barium hydroxide claim 2 , sodium carbonate claim 2 , sodium bicarbonate claim 2 , potassium carbonate claim 2 , potassium bicarbonate claim 2 , and mixtures thereof.4. The method of claim 1 , wherein the medium is selected from the group consisting of methanol claim 1 , ethanol claim 1 , propanol claim 1 , isopropanol claim 1 , butanol claim 1 , isobutanol claim 1 , tert-butanol claim 1 , acetone claim 1 , tetrahydrofuran claim 1 , dioxane claim 1 , dimethylformamide claim 1 , dimethylacetamide claim 1 , dimethyl sulfoxide claim 1 , acetonitrile claim 1 , diethylether claim 1 , ethyl acetate claim 1 , dimethylacetamide claim 1 , and mixtures thereof. 1. Field of the InventionThe present invention relates to a method for preparing racemic or optically ...

Подробнее
Номер записи: 41
14-01-2021 дата публикации

Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents

Номер: US20210008203A1
Автор: Pinchuk Anatoly, Tomé Wolfgang Axel, Weichert Jamey
Принадлежит:

Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: 2. The compound of claim 1 , wherein the one or more gadolinium atoms are in the form of a Gd(III) ion.3. The compound of claim 1 , wherein a is 1 (aliphatic aryl-alkyl chain).4. The compound of claim 1 , wherein a is 0 (aliphatic alkyl chain).5. The compound of claim 1 , wherein m is 1 (acylphospholipid series).6. The compound of claim 5 , wherein n is an integer between 12 and 20.7. The compound of claim 5 , wherein Y is —OCOX claim 5 , —COOX or —OX.8. The compound of claim 7 , wherein X is —CHCHor —CH.9. The compound of claim 1 , wherein m is 0 (alkylphospholipid series).10. The compound of claim 1 , wherein b is 1.11. The compound of claim 1 , wherein n is 18.12. The compound of claim 1 , wherein Ris —NZ.13. The compound of claim 12 , wherein each Z is independently —CHCHor —CH.14. The compound of claim 13 , wherein each Z is —CH.15. A composition comprising a compound according to and a pharmaceutically acceptable carrier.16. A method for detecting or imaging one or more cancer tumor cells in a biological sample claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) contacting the biological sample with a compound of ; and'}(b) identifying individual cells or regions within the biological sample that are emitting signals characteristic of gadolinium, whereby one or more cancer tumor cells are detected or imaged.17. The method of claim 16 , wherein the step of identifying individual cells or regions within the biological sample that are emitting signals characteristic of gadolinium is performed by magnetic resonance imaging (MRI).18. The method of claim 16 , wherein the biological sample is part or all of a subject.19. A method of diagnosing cancer in a subject claim 16 , comprising performing the method of claim 16 , wherein the biogical sample is obtained from ...

Подробнее
Номер записи: 42
03-02-2022 дата публикации

PROCESS FOR PREPARING ALDEHYDES AND SEPARATION OF THE CATALYST SYSTEM BY MEMBRANE SEPARATION

Номер: US20220033337A1
Автор: BRÄCHER Alexander, Franke Robert, Fridag Dirk, GLUTH Frederik, Knossalla Johannes, Kubis Christoph, KUCMIERCZYK Peter, MARKOVIC Ana, SALE Anna Chiara, Schäpertöns Marc
Принадлежит: EVONIK OPERATIONS GMBH

The present invention provides a process for preparing aldehydes from C2 to C20 olefins using a subsequent membrane separation to separate the homogeneously dissolved catalyst system, wherein prior to the membrane separation a gas exchange that increases the partial pressure fraction of carbon monoxide or hydrogen is carried out in order to boost catalyst retention by the membrane. 1. A process for preparing aldehydes , said process comprising at least{'sub': '2', 'a hydroformylation through the reaction of C2 to C20 olefins with syngas in the presence of a homogeneously dissolved catalyst system that comprises at least Co or Rh, in at least one reaction zone, yielding a liquid reaction output containing the product, wherein the partial pressure fraction of CO or Hin the hydroformylation constitutes not more than 75% of the total gas pressure, the total gas pressure being the sum of the pressures occurring from all the gaseous substances present, and'}a membrane separation for separating the homogeneously dissolved catalyst system, wherein,{'sub': 2', '2, 'before the membrane separation, a gas exchange with CO or His carried out, as a result of which the partial pressure fraction of CO or Hconstitutes more than 80% of the total gas pressure.'}2. The process according to claim 1 , wherein the hydroformylation is carried out at a pressure of from 10 to 350 bar.3. The process according to claim 1 , wherein the hydroformylation is carried out at a temperature of from 80 to 250° C.4. The process according to claim 1 , wherein the homogeneously dissolved catalyst system comprises at least Rh and a phosphorus-containing ligand.5. The process according to claim 1 , wherein the phosphorus-containing ligand is a phosphine claim 1 , a monophosphite claim 1 , a bisphosphite or mixtures thereof.6. The process according to claim 1 , wherein the total gas pressure after the gas exchange is from 1 to 70 bar.7. The process according to claim 1 , wherein the membrane separation is ...

Подробнее
Номер записи: 43
21-01-2016 дата публикации

GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS

Номер: US20160015820A1
Автор: Bar-On Zohar, Ben Dror Gai, Farkash Orly, Pelled Dori, Platt Dorit, Richter Yael, Shulman Avidor, Zuabi Rassan
Принадлежит: ENZYMOTEC LTD.

The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.

Подробнее
Номер записи: 44
21-01-2016 дата публикации

Process for manufacture of gadofosveset trisodium monohydrate

Номер: US20160016979A1
Автор: Franz-Willi Herkenrath, Jan Haller, Nicolas Champion, Tarakeshwar Anklekar
Принадлежит: Finorga SAS, Lantheus Medical Imaging Inc

This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.

Подробнее
Номер записи: 45
18-01-2018 дата публикации

PHOSPHOROUS ACID COMPOUND, METHOD FOR PRODUCING SAID COMPOUND, AND USE OF SAID COMPOUND

Номер: US20180016417A1
Автор: KIMURA Natsuko, MATSUMOTO SHUHEI
Принадлежит: Sumitomo Chemical Company, Limited

The present invention relates to a phosphorous acid compound represented by formula (I): 3. A stabilizer for an organic material claim 1 , containing the phosphorous compound according to .4. The stabilizer according to claim 3 , wherein the organic material is a thermoplastic resin.5. The stabilizer according to claim 4 , wherein the thermoplastic resin is a polyolefin or an engineering plastic.6. A method for stabilizing an organic material claim 1 , wherein the phosphorous acid compound according to is added to an organic material.7. The stabilization method according to claim 6 , wherein the organic material is a thermoplastic resin.8. The stabilization method according to claim 7 , wherein the thermoplastic resin is a polyolefin or an engineering plastic.9. A stabilized organic material composition containing an organic material claim 1 , and the phosphorous acid compound according to .10. The composition according to claim 9 , wherein the organic material is a thermoplastic resin.11. The composition according to claim 10 , wherein the thermoplastic resin is a polyolefin or an engineering plastic. The present application claims priority of Japanese Patent Application No. 2015-025727 (filing date: Feb. 12, 2015), the entire contents of which are hereby incorporated by reference.The present invention relates to a novel phosphorous acid compound, a method for producing said compound, and use of said compound as a stabilizer for organic materials.It is known that organic materials such as thermoplastic resins, thermosetting resins, natural or synthetic rubbers, mineral oils, lubricants, adhesives, and paints are deteriorated through the action of heat, oxygen or the like during production or use, which are accompanied by deterioration in strength and physical properties, changes in flowability, coloring, and deterioration in surface physical properties of the organic materials attributable to phenomena including molecular cleavage and molecular crosslinkage, ...

Подробнее
Номер записи: 46
21-01-2021 дата публикации

SPHINGOMYELIN-DERIVED LIPID AND METHOD FOR PRODUCING SAME

Номер: US20210017202A1
Автор: OTA Masaki
Принадлежит: NOF CORPORATION

The invention aims to provide a constituent component of a liposome for a DDS carrier that does not show a membrane fusion promoting effect on viruses. In particular, the invention provides a sphingomyelin-derived lipid represented by the formula (1): 2. The sphingomyelin-derived lipid according to claim 1 , wherein Ris an alkyl group having 15 carbon atoms.3. The sphingomyelin-derived lipid according to claim 1 , wherein Ris an acyl group having 16-20 carbon atoms.4. A method for producing the sphingomyelin-derived lipid according to claim 1 , comprising a step of mixing sphingomyelin and palladium carbon in lower alcohol in the presence of cyclohexene.5. The production method according to claim 4 , wherein the sphingomyelin is a sphingomyelin derived from egg yolk.6. The production method according to claim 4 , wherein the lower alcohol is a monohydric alcohol having 1-3 carbon atoms.7. The sphingomyelin-derived lipid according to claim 2 , wherein Ris an acyl group having 16-20 carbon atoms.8. The production method according to claim 5 , wherein the lower alcohol is a monohydric alcohol having 1-3 carbon atoms. The present invention relates to a sphingomyelin-derived lipid that can be utilized for pharmaceutical use and cosmetic use, and a production method thereof.In the field of drug delivery system (DDS), the research of pharmaceutical products using a liposome constituted of phospholipid, sphingolipid, cholesterol and the like as a carrier has been actively performed, and several products are available on the market. Liposomes can suppress the side effects of internally encapsulated drugs, or prevent decomposition of compounds unstable in the body. In addition, various functions can be imparted to the liposomes by modifying the liposome surface. For example, liposomes modified with polyethylene glycol can improve blood retention property compared with liposomes without the modification.Some of the drugs that are encapsulated in liposomes require an acidic ...

Подробнее
Номер записи: 47
22-01-2015 дата публикации

Processes For Forming Alkylated Aryl Phosphite Compositions From Complex Hydrocarbon Streams

Номер: US20150021523A1
Автор: Jonathan S. Hill, Maurice Power, Paul Stott, Peter Smith
Принадлежит: Addivant USA LLC

Processes for alkylating hydroxyaryl compounds by reacting a hydroxyaryl with at least one olefin of a complex hydrocarbon stream. The complex hydrocarbon stream preferably comprises a fraction of a cracked hydrocarbon feed stream or the reaction products of a dehydrogenation of a paraffinic feedstock. The olefin of the complex hydrocarbon stream is preferably a branched olefin, e.g., isobutylene or isoamylene. The alkylated compositions are suitable for forming liquid phosphite compositions.

Подробнее
Номер записи: 48
26-01-2017 дата публикации

PHOSPHAPHENANTHRENE-BASED COMPOUND AND RELATED PREPARATION METHOD AND APPLICATION

Номер: US20170022228A1
Автор: CHEN XING-FA, HSIEH CHEN-YU, HU ZHI-LONG, XIONG XIANG
Принадлежит:

Provided is a phosphaphenanthrene-based compound represented by the following chemical structure: 2. The phosphaphenanthrene-based compound according to claim 1 , wherein R and R′ are each independently a vinyl- and carbonyl-substituted alkyl group with 3 to 20 carbon atoms claim 1 , a vinyl- and carbonyl-substituted cycloalkyl group with 8 to 20 carbon atoms claim 1 , a vinyl- and carbonyl-substituted benzyl group with 9 to 20 carbon atoms or a vinyl- and carbonyl-substituted aromatic group with 8 to 20 carbon atoms.3. The phosphaphenanthrene-based compound according to claim 1 , wherein R and R′ are each independently a vinyl-substituted alkyl group with 3 to 20 carbon atoms claim 1 , or a vinyl-substituted benzyl group with 9 to 20 carbon atoms.9. The method of manufacturing a phosphaphenanthrene-based compound according to claim 8 , wherein the dialdehyde compound is at least one selected from the group consisting of the following: 1 claim 8 ,4-phthalaldehyde claim 8 ,1 claim 8 ,3-phthalaldehyde claim 8 ,1 claim 8 ,2-phthalaldehyde claim 8 , 2 claim 8 ,3-naphthalenedicarboxaldehyde claim 8 , 1 claim 8 ,6-naphthalenedicarboxaldehyde claim 8 , 1 claim 8 ,8-naphthalenedicarboxaldehyde claim 8 , 1 claim 8 ,7-naphthalenedicarboxaldehyde claim 8 , 4 claim 8 ,4′-biphenyldicarboxaldehyde claim 8 , 4 claim 8 ,4′-xenygloxal claim 8 , bisphenol A based dialdehyde claim 8 , bisphenol F based dialdehyde claim 8 , and bisphenol E based dialdehyde.10. The method of manufacturing a phosphaphenanthrene-based compound according to claim 8 , wherein a mole ratio of the 9 claim 8 ,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide and the dialdehyde compound ranges from 2:1 to 4:1.11. A resin composition comprising the phosphaphenanthrene-based compound according to .12. The resin composition according to claim 11 , wherein the resin composition comprises a reactant claim 11 , an amount of the reactant is 100 parts by weight claim 11 , an amount of the phosphaphenanthrene-based ...

Подробнее
Номер записи: 49
10-02-2022 дата публикации

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION

Номер: US20220041633A1
Автор: Ashworth-Sharpe Julia, Bieniarz Christopher, Kelly Brian D., Polaske Nathan
Принадлежит:

Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step. 1. A method of detecting a first target in a biological sample , comprising:contacting the biological sample with a first detection probe specific to the first target;labeling the first target with a first enzyme through the first detection probe;contacting the biological sample with a first quinone methide analog precursor comprising a first enzyme recognition group and a first detectable label, anddetecting the first target by detecting the first detectable label.2. The method of claim 1 , wherein the first enzyme cleaves the first enzyme recognition group claim 1 , thereby converting the first quinone methide analog precursor into a first reactive quinone methide analog which covalently binds to the biological sample proximally to or directly on the first target.3. The method of claim 1 , wherein the first enzyme is a phosphatase claim 1 , phosphodiesterase claim 1 , esterase claim 1 , lipase claim 1 , amidase claim 1 , protease claim 1 , nitroreductase claim 1 , urease claim 1 , sulfatase claim 1 , cytochrome P450 claim 1 , alpha-glucosidase claim 1 , beta-glucosidase claim 1 , beta-lactamase claim 1 , alpha-glucoronidase claim 1 , beta-glucoronidase claim 1 , alpha-galactosidase claim 1 , beta- ...

Подробнее
Номер записи: 50
28-01-2021 дата публикации

PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES

Номер: US20210024553A1
Автор: BAZIN-LEE Helene G., BESS Laura S., Johnson David A.
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines. 211.-. (canceled)12. The process of wherein 1H-tetrazole is added to a compound of formula (III) or formula (IV).13. The process of wherein 1H-tetrazole is added in several portions over 20 to 40 minutes.14. The process of wherein imidazolium triflate is added with a compound of formula (VII) or (VIII).15. The process of wherein the coupling agent used with a compound of formula (III) or formula (IV) and a compound of formula (V) is at 2.1 equivalents claim 1 , the compound of formula (III) or formula (IV) is at 2.0 equivalents claim 1 , the compound of formula (V) is at 2.1 equivalents claim 1 , the compound of formula (VII) or formula (VIII) is at 1.0 equivalent and the oxidizing agent for the compound of formula (IX) is at 1.5 equivalent.16. The process of wherein imidazolium triflate is added with the compound of formula (VII) or the compound of formula (VIII) to the same reaction mixture produced by the reaction of compound of formula (V) with the compound of formula (III) or the compound of formula (IV).17. The process of wherein the reaction mixture containing the compound of formula (VI) is cooled to 0° C. before the addition of a compound of formula (VII) or formula (VIII).18. The process of wherein the hydroxyl protecting group is cyanoethyl and deprotection is with triethylamine (TEA).20. The process of wherein 1H-tetrazole is added to a compound of formula (III) or formula (IV).21. The process of wherein 1H-tetrazole is added in several portions over 20 to 40 minutes.22. ...

Подробнее
Номер записи: 51
02-02-2017 дата публикации

POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS

Номер: US20170029448A1
Автор: Gebeyehu Gulilat, JESSEE Joel
Принадлежит: MOLECULAR TRANSFER, INC.

New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes. The present invention is in the field of molecular biology, and more particularly in the field of transfection, which utilizes new compounds and methods for the introduction of nucleic acids into eukaryotic cells. 2. The compound of claim 1 , wherein:{'sup': 2', '2', '2', '2', '2, 'each X independently is selected from —O—, —C(O)O—, —O(O)C—, —N(R)C(O)O—, —C(O)N(R)—, —OC(O)N(R)—, and —(R)NCON(R)—;'}{'sub': 1', '4, 'Y is independently (C-C)alkyl;'}{'sub': 1', '20', '2', '20', '2', '20, 'each R is independently selected from substituted or unsubstituted (C-C)alkyl, substituted or unsubstituted (C-C)alkenyl, and substituted or unsubstituted (C-C)alkynyl;'}{'sup': 1', '11, 'sub': 1', '6', '2', '2, 'Ris independently selected from (C-C)alkyl, C(O)R, and CHCH(OH)CH(OH);'}{'sup': '2', 'sub': 1', '4, 'Ris independently selected from hydrogen and (C-C)alkyl;'}{'sup': '3', 'sub': 2', 'j', '2', '2', '3', '2', '3', '2', '2', '3', '2', '2', '2', '3', '2', '2', '2', '4', '2', '2', '2', '3', '2', '2', '2', '3', '3', '2', '2', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris independently selected from —(CH)NH, —C(O)CH[(CH)NH(CH)NH]—[NH(CH)NH], C(O)CH(NH)(CH)NH; —C(O)CH(NH)(CH)NH, —C(O)CH(NH)(CH)NHC(═NH)NH, —C(O)CH(NH)(CH)(CHN), —C(O)CH(NH)(CH)NH, —C(O)CH(NH)CHNH, —C(O)CH(NH)(CH)NH, and —C(O)CH(NH)CHOH;'}{'sup': '11', 'sub': 1', '6', '2', '6', '2', '6', '3', '8, 'Ris independently selected from hydrogen, (C-C)alkyl, (C-C)alkenyl, (C-C)alkynyl, trifluoromethyl, and (C-C)cycloalkyl.'}3. The compound of claim 2 , wherein:{'sup': '2', 'each X independently is selected from —C(O)O—, —O(O)C—, and —C(O)N(R)—;'}{'sub': 2', '3, 'Y is independently (C-C)alkyl;'}{'sub': 1', '20', '2', '20', '2', '20, ...

Подробнее
Номер записи: 52
02-02-2017 дата публикации

METHOD FOR ACQUIRING ONE OR A PLURALITY OF RECYCLABLE MATERIALS FROM SEEDS

Номер: US20170029449A1
Автор: BOSZULAK Wladislawa, HRUSCHKA Steffen, ULLMANN Detlef
Принадлежит:

A method for acquiring at least one or a plurality of recyclable materials, in particular phytic acid, from a native material quantity containing phytic acid or phytate is provided. The method involves providing a native, reduced material quantity containing phytic acid and/or phytate made from seeds containing phytic acid. The reduced material quantity is pre-treated in order to obtain a flowable alkaline, preferably alcoholic-alkaline mash. A solid phase, which has phytic acid and/or at least one phytate, is separated from the mash. Phytic acid and/or at least one phytate is isolated from the solid phase. 117-. (canceled)18. A method for obtaining at least one or a plurality of recyclable materials from a native material quantity containing phytic acid or phytate , wherein the at least one recyclable material is phytic acid or at least one phytate , the method comprising:Step A: supplying a native material quantity containing phytic acid or phytate from seeds containing phytic acid or phytate with hard, breakable shells as material quantity from the whole seeds or from seeds that have been at least partially de-oiled as expeller meal or as press cake left over as residue from oil extraction with a press;Step B: if the material quantity from step A has not yet been comminuted, then comminuting the material quantity so that the shells are broken open;{'b': '8', 'Step C: dispersing the comminuted material quantity from step A) or B) with water or with an aqueous solution, wherein up to parts maximum of water are added to one part of comminuted material quantity and wherein the water and the comminuted material quantity are stirred so as to give rise to a flowable mash or a dispersion;'}Step D): adjusting a pH value of the mash from step C) in an alkaline range of pH >9.5;Step E): adding a diluted water-soluble organic solvent to the mash D) subsequent to the adjustment of the pH of the mash in step D) in such a way that an alcohol concentration is reached that is ...

Подробнее
Номер записи: 53
17-02-2022 дата публикации

CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING

Номер: US20220047725A1
Автор: Eilon Tal, Green Ori, Hananya Nir, Satchi-Fainaro Ronit, Shabat Doron
Принадлежит:

The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging. 3. The conjugate of claim 2 , wherein Rand Rtogether with the carbon atom to which they are attached form adamantyl.4. The conjugate of claim 2 , wherein Xis —(CH)-para-phenylene; and Xis —C(O)—.5. The conjugate of claim 1 , wherein:{'sup': '1', 'sub': 1', '8, 'Ris a linear or branched (C-C)alkyl;'}{'sup': 2', '3, 'Rand Rtogether with the carbon atom to which they are attached form a fused, spiro or bridged polycyclic ring;'}{'sup': 7', '8', '9', '7', '8', '9, 'sub': '2', 'at least one of R, Rand Ris H, and the other of R, Rand Reach independently is an electron acceptor group selected from the group consisting of halogen, —NOand —CN; and'}{'sub': 1', '2', '1', '1', '18', '6', '14', '1', '18', '6', '14', '2', '2', '2', '2', '2', '3', '6', '10', '1', '4', '6', '10', '1', '4', '1', '18', '1', '8', '6', '10', '6', '10', '2, 'X is a linker of the formula —X—X—, wherein Xis (C-C)alkylene, (C-C)arylene-diyl, or (C-C)alkylene-(C-C)arylene-diyl, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH, —CN, —NO, —SH, —OH, —NH, —CONH, —SOH, —SOH, —S(═O)H, (C-C)aryl, (C-C)alkylene-(C-C)aryl, heteroaryl, and (C-C)alkylene-heteroaryl, and said (C-C)alkylene being further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, and/or at least one group each independently selected from the group consisting of —NH—CO—, —CO—NH—, —N(C-Calkyl)-, —N(C-Caryl)-, (C-C)arylene-diyl, and heteroarylenediyl; and Xis —C(O)—.'}6. The conjugate of claim 5 , wherein Ris methyl; Rand Rtogether with the carbon atom to which they are attached form adamantly; Xis —(CH)-para-phenylene; ...

Подробнее
Номер записи: 54
30-01-2020 дата публикации

LIPID DERIVATIVE FOR NUCLEIC ACID INTRODUCTION

Номер: US20200031853A1
Автор: ASAI Tomohiro, FUKATA Naofumi, MAEDA Noriyuki, Oku Naoto, TOMITA Koji
Принадлежит:

An object is to provide a lipid particle that is not positively charged at a pH of the body fluid (typically in the neutral range), and that enables efficient onset of the effect of a medicinal substance encapsulated in the lipid particle; and to provide a lipid for forming the lipid particle. The object is achieved by the phospholipid represented by formula (1), and a lipid particle containing the phospholipid: 2. The phospholipid according to claim 1 , wherein the chain hydrocarbon group is an unsaturated chain hydrocarbon group.3. The phospholipid according to claim 1 , wherein the chain hydrocarbon group has 12 to 24 carbon atoms.4. The phospholipid according to claim 1 , wherein m and n are both 2.5. The phospholipid according to claim 1 , wherein p is 1 or 2.6. A lipid particle comprising the phospholipid of (phospholipid A).7. The lipid particle according to claim 6 , in which a medicinal substance is encapsulated.8. The lipid particle according to claim 7 , wherein the medicinal substance is a polynucleotide.9. The lipid particle according to claim 6 , further comprising cholesterol.10. The lipid particle according to claim 6 , further comprising a phospholipid having a saturated chain hydrocarbon group (phospholipid B) claim 6 , wherein the phospholipid A has an unsaturated chain hydrocarbon group.11. The lipid particle according to claim 10 , wherein the phospholipid B is present in an amount of 30 to 70 mol claim 10 , per 100 mol of the phospholipid A.12. A method for producing a lipid particle claim 1 , the method comprising mixing an alcohol solution containing the phospholipid of with an acid aqueous solution containing a water-soluble medicinal substance.13. The method according to claim 12 , wherein the water-soluble medicinal substance is a polynucleotide.14. The method according to claim 12 , wherein the alcohol solution contains butanol as a solvent.15. A medical drug comprising a lipid particle containing the phospholipid of claim 1 , and a ...

Подробнее
Номер записи: 55
04-02-2016 дата публикации

NEAR-INFRARED-RAY-ABSORBING COMPOSITION, NEAR-INFRARED-RAY CUT FILTER USING SAME, MANUFACTURING METHOD THEREFOR, CAMERA MODULE, AND MANUFACTURING METHOD THEREFOR

Номер: US20160037034A1
Автор: HITOMI Seiichi, Inasaki Takeshi, KAWASHIMA Takashi, SASAKI Kouitsu
Принадлежит: FUJIFILM Corporation

Provided are a near-infrared-ray-absorbing composition having strong near-infrared shielding properties when a cured film is produced, a near-infrared-ray cut filter, a manufacturing method therefor, a camera module, and a manufacturing method therefor. The near-infrared-ray-absorbing composition includes a copper complex obtained by reacting a compound (A) having at least two coordination sites with a copper component. 1. A near-infrared-ray-absorbing composition comprising:a copper complex obtained by reacting a compound (A) having at least two coordination sites with a copper component.2. A near-infrared-ray-absorbing composition comprising:a copper complex obtained by reacting a compound (A1) having two monoanionic coordination sites or a compound having a salt of the compound (A1) with a copper component.3. The near-infrared-ray-absorbing composition according to claim 1 ,wherein the compound (A) is a compound (A2) respectively having at least one coordination site to be coordinated with an anion and at least one coordinating atom to be coordinated with an unshared electron pair.4. The near-infrared-ray-absorbing composition according to claim 1 ,wherein the compound (A) is a compound (A3) having two or more coordinating atoms to be coordinated with an unshared electron pair.5. The near-infrared-ray-absorbing composition according to claim 2 , {'br': None, 'sup': 1', '1', '2, 'X-L-X\u2003\u2003Formula (10)'}, 'wherein the compound (A1) is represented by Formula (10) described below{'sup': 1', '2', '1', 'N1', 'N1, 'sub': '2', 'wherein, in Formula (10), each of Xand Xindependently represents the monoanionic coordination site, and Lrepresents an alkylene group, an alkenylene group, an arylene group, a heterocyclic group, —O—, —S—, —NR—, —CO—, —CS—, —SO—, or a divalent linking group formed of a combination thereof; here, Rrepresents a hydrogen atom, an alkyl group, an aryl group, or an aralkyl group.'}11. The near-infrared-ray-absorbing composition according to ...

Подробнее
Номер записи: 56
11-02-2016 дата публикации

PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE

Номер: US20160039872A1
Автор: Burke, JR. Terrence R., Kelley James A., Lai Christopher C., Lee Kyung S., PARK Jung Eun, QIAN Wenjian
Принадлежит:

The invention provides novel compounds that may serve as anticancer therapeutics. The compounds of the invention bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds of the invention are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected pho-phoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives of the invention have achieved both good efficacy and an enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Further, the invention provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents. 14.-. (canceled)6. The compound of any one of claim 5 , wherein Xis CHC(O)— claim 5 , and Rand Rare both H.8. The compound of claim 7 , wherein one of Rand Ris (C)alkyl-C(O)O—(C)alkyl- claim 7 , and the other is selected from the group of H claim 7 , (C)alkyl-C(O)O—(C)alkyl- claim 7 , aryl-(C)alkyl- claim 7 , and (C)alkyl optionally substituted by one or more hydroxyl groups.9. The compound of claim 8 , wherein one of Rand Ris t-Bu-C(O)O—CH— (“POM”) claim 8 , and the other is selected from the group of H claim 8 , t-Bu-C(O)O—CH— claim 8 , —(CH)OH claim 8 , and benzyl.10. The compound of claim 7 , wherein Ris H or —OH.11. The compound of claim 7 , wherein Ris phenyl-(C)alkyl.12. The compound of claim 7 , wherein Ris (C)alkyl optionally substituted by one or more (C)alkoxyl or hydroxyl groups.13. The compound of claim 7 , wherein Ris (C)alkyl.15. The compound of claim 7 , wherein one of Rand Ris H claim 7 , and the other is selected from the group of allyl-(C)alkyl claim 7 , aryl-(C)alkyl- claim 7 , heteroaryl-(C)alkyl claim 7 , and (C)alkyl optionally substituted by one or more carboxyl or hydroxyl groups.16. The compound of claim 7 , wherein Ris H.17. The compound of claim 7 , wherein Ris aryl-(C)alkyl.18. The compound of claim 7 ...

Подробнее
Номер записи: 57
09-02-2017 дата публикации

NEW LIPOPHENOL COMPOUNDS AND USES THEREOF

Номер: US20170037067A1
Автор: BRABET Philippe, CIA David, CRAUSTE Céline, DURAND Thierry, GUILLOU Laurent, Hamel Christian, VERCAUTEREN Joseph, VIGOR Claire
Принадлежит:

The present invention relates to a compound of formula (I) wherein: —i is 0 or 1; j is 0 or 1; k is 0 or 1; —Rand Rare in particular H, (C-C)alkyl, or a group of formula C(O)R; —R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; —Ris H and k=0 when j=1; or, when j=0, Ris —C(O)R or -L-C(O)R; —L, U and L″ are linkers; wherein, when j=0, at least one of the groups R; Rand Rcomprises a radical R. 2. The compound of claim 1 , wherein claim 1 , when j=0 claim 1 , at most one of the groups R claim 1 , Rand Ris H.5. The compound of claim 4 , wherein Ris an alkyl group.10. The compound of claim 1 , wherein Ris a (C-C)alkyl group claim 1 , preferably a (C-C)alkyl group claim 1 , and more preferably an isopropyl group.11. The compound of claim 1 , wherein R is a linear or branched alkyl group claim 1 , possibly interrupted by one or several double bonds claim 1 , comprising from 19 to 23 carbon atoms.12. The compound of claim 1 , wherein R is a linear or branched alkyl group claim 1 , possibly interrupted by one or several double bonds claim 1 , comprising from 19 to 23 carbon atoms claim 1 , and wherein one or several hydrogen atoms are replaced by deuterium atoms.13. The compound of claim 1 , wherein R is a linear or branched alkyl group claim 1 , interrupted by at least one double bond claim 1 , comprising from 19 to 21 carbon atoms.16. A pharmaceutical composition comprising the compound according to claim 1 , in association with a pharmaceutically acceptable vehicle.17. A method for treating a pathology involving both carbonyl and oxidative stress claim 1 , comprising a step of administering a pharmaceutically acceptable amount of the compound of to a patient in need thereof.18. The compound of claim 17 , wherein the pathology involving carbonyl and oxidative stress is chosen from the group consisting of: inflammatory and infectious diseases claim 17 , cardiovascular diseases claim 17 , metabolic diseases claim 17 , cancer claim 17 , retinal ...

Подробнее
Номер записи: 58
24-02-2022 дата публикации

6,6'-([1,1'-BIPHENYL]-2,3'-DIYLBIS(OXY))DIDIBENZO[D,F][1,3,2]DIOXAPHOSPHEPINES

Номер: US20220056059A1
Автор: BÖRNER Armin, Franke Robert, Kloss Svenja, SELENT Detlef
Принадлежит: EVONIK OPERATIONS GMBH

6,6′-([1,1′-Biphenyl]-2,3′,-diylbis)oxy))didibenzo[d,f][1,3,2]dioxaphosphepines and the use thereof in hydroformylation. 2. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare selected from: —H claim 1 , —(C-C) alkyl.3. Compound according to claim 1 , where at least one of the radicals R claim 1 , R claim 1 , R claim 1 , Ris —H.4. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare —H.5. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare selected from: —H claim 1 , —O—(C-C) alkyl.6. Compound according to claim 1 , where at least one of the radicals R claim 1 , R claim 1 , R claim 1 , Ris —H.7. Compound according to claim 1 , where R claim 1 , R claim 1 , R claim 1 , Rare —H.9. Use of a compound according to in a ligand-metal complex for catalysis of a hydroformylation reaction.10. Process comprising the process steps of:a) initially charging an olefin,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) adding a compound according to and a substance containing a metal selected from: Rh, Ru, Co, Ir,'}{'sub': '2', 'c) feeding in Hand CO,'}d) heating the reaction mixture from steps a) to c), with conversion of the olefin to an aldehyde. The invention relates to 6,6′-([1,1′-biphenyl]-2,3′-diylbis(oxy))didibenzo[d,f][1,3,2]dioxaphosphepines and to the use thereof in hydroformylation.Phosphorus-containing compounds play a crucial role as ligands in a multitude of reactions, e.g. in hydrogenation, in hydrocyanation and also in hydroformylation.The reactions between olefin compounds, carbon monoxide and hydrogen in the presence of a catalyst to give the aldehydes with one carbon atom more are known as hydroformylation or the oxo process. Catalysts used in these reactions are frequently compounds of the transition metals of group VIII of the periodic table of the elements. Known ligands are, for example, compounds from the phosphine, phosphite and phosphonite classes, each containing trivalent ...

Подробнее
Номер записи: 59
24-02-2022 дата публикации

NEW DIPHOSPHITES BASED ON CIS-BUTENE-1,4-DIOL

Номер: US20220056060A1
Автор: BÖRNER Armin, Franke Robert, SALE Anna Chiara, SELENT Detlef
Принадлежит: EVONIK OPERATIONS GMBH

New diphosphites based on cis-butene-1,4-diol. 2. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8'], 'sub': ['1', '12'], '#text': 'where R, R, R, Rare selected from: —H, —(C-C) alkyl.'}3. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8', 'l'], '#text': 'where the radicals R, R, R, Rare not all simultaneously —Bu.'}4. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8', 'l'], '#text': 'where the radicals R, R, R, Rare not —Bu.'}5. Compound according to claim 1 ,{'sup': ['1', '4', '5', '8'], '#text': 'where at least one of the radicals R, R, R, Ris —H.'}6. Compound according to claim 1 ,{'sup': ['2', '3', '6', '7'], 'sub': ['1', '12'], '#text': 'where R, R, R, Rare selected from: —H, —O—(C-C) alkyl.'}7. Compound according to claim 1 ,{'sup': ['2', '3', '6', '7'], '#text': 'where at least one of the radicals R, R, R, Ris —H.'}8. Compound according to claim 1 ,where the compound has the structure (I).10. Compound according to claim 1 ,where the compound has the structure (II).12. Use of a compound according to in a ligand-metal complex for catalysis of a hydroformylation reaction.13. Process comprising the process steps of:a) initially charging an olefin,{'claim-ref': {'@idref': 'CLM-00001', '#text': 'claim 1'}, '#text': 'b) adding a compound according to and a substance containing a metal selected from: Rh, Ru, Co, Ir,'}{'sub': '2', '#text': 'c) feeding in Hand CO,'}d) heating the reaction mixture from steps a) to c), with conversion of the olefin to an aldehyde. The invention relates to new diphosphites based on cis-butene-1,4-diol.Phosphorus-containing compounds play a crucial role as ligands in a multitude of reactions, e.g. in hydrogenation, in hydrocyanation and also in hydroformylation.The reactions between olefin compounds, carbon monoxide and hydrogen in the presence of a catalyst to give the aldehydes with one carbon atom more are known as hydroformylation or the oxo process. Catalysts used in these reactions are frequently compounds ...

Подробнее
Номер записи: 60
06-02-2020 дата публикации

A method for making a solid-supported phospholipid bilayer

Номер: US20200040017A1
Автор: Joshua Alexander JACKMAN, Nam-Joon Cho
Принадлежит: NANYANG TECHNOLOGICAL UNIVERSITY

A method of preparing a solid-supported phospholipid bilayer is provided. The method includes a) a first step of providing a solution comprising a bicellar mixture of a long-chain phospholipid and a short-chain phospholipid; b) at least one second step of decreasing the temperature of the solution to below 0° C., increasing the temperature to above room temperature and causing the solution to be blended; and c) a third step of depositing the solution obtained after the second step on a surface of a support, wherein the concentration of the long-chain phospholipid in the solution is at most 0.1 mg/mL, for obtaining a solid-supported phospholipid bilayer. A solid-supported phospholipid layer obtained by the method as defined above is also provided.

Подробнее
Номер записи: 61
01-05-2014 дата публикации

COMPOUNDS AND COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS CONDITIONS, INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER

Номер: US20140121185A1
Автор: RIGAS Basil
Принадлежит: MEDICON PHARMACEUTICALS, INC.

Novel compounds and pharmaceutical compositions thereof for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever. 3. The compound according to claim 1 , wherein Zis hydrogen.4. The compound according to claim 1 , wherein Zis farnesyl.9. The compound according to any one of to claim 1 , wherein Xis —NR— claim 1 , Ris hydrogen; B is —(CH)—; and Zis represented by Formula Z-1 claim 1 , Rand Rbeing identical C-alkyl substituents.10. The compound according to any one of to claim 1 , wherein Xis —NH—; B is —(CH)—; and Zis represented by Formula Z-1 claim 1 , Rand Rbeing identical C-alkyl substituents.11. A compound according to any one of to for use in the treatment and/or prevention of disorders selected from the group consisting of inflammation claim 1 , pain claim 1 , fever claim 1 , cancer and precancerous conditions.12. The compound according to claim 11 , wherein the disorder is a cancer with a mutant Ras gene such as pancreatic cancer.13. A pharmaceutical composition comprising the compound according to any of to for use in the treatment and/or prevention of disorders selected from the group consisting of inflammation claim 11 , pain claim 11 , fever claim 11 , cancer or precancerous conditions.14. The pharmaceutical composition according to claim 13 , wherein said pharmaceutical composition is formulated in the form of nanoparticles.15. The pharmaceutical composition according to or claim 13 , wherein said pharmaceutical composition further comprises one or more additional compounds having anti-cancer activity.16. A compound selected from the group consisting of compounds 1 to 169.1723-. (canceled)24. A pharmaceutical composition comprising compound of . The invention is directed to compounds and pharmaceutical compositions for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever.Cancer remains the major cause of mortality in the ...

Подробнее
Номер записи: 62
15-02-2018 дата публикации

COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF INFLAMMATORY, DEGENERATIVE, AND NEURODEGENERATIVE DISEASES

Номер: US20180044278A1
Автор: Bazan Nicolas G., PETASIS Nicos A.
Принадлежит:

This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions. 2. The composition of claim 1 , wherein n is a number selected from a group consisting of 0 to 13.3. The composition of claim 1 , wherein n is selected from a group consisting of 1 claim 1 , 3 claim 1 , 5 claim 1 , 7 claim 1 , 9 claim 1 , 11 or 13.4. The composition of claim 1 , wherein n is selected from a group consisting of 0 claim 1 , 2 claim 1 , 4 claim 1 , 6 claim 1 , 8 claim 1 , 10 or 12.6. The compound of claim 5 , wherein n is a number selected from a group consisting of 0 to 13.7. The compound of claim 5 , wherein n is selected from a group consisting of 1 claim 5 , 3 claim 5 , 5 claim 5 , 7 claim 5 , 9 claim 5 , 11 or 13.8. The compound of claim 5 , wherein n is selected from a group consisting of 0 claim 5 , 2 claim 5 , 4 claim 5 , 6 claim 5 , 8 claim 5 , 10 or 12.9. The compound of claim 5 , wherein n is 9 or 11.10. The compound of claim 5 , wherein the R group is methyl or ethyl.11. The compound of claim 5 , wherein the R group is a metal cation selected from a group consisting of sodium claim 5 , potassium claim 5 , magnesium claim 5 , zinc claim 5 , and calcium cation.14. The compound of claim 13 , wherein n is a number selected from a group consisting of 0 to 13.15. The compound of claim 13 , wherein n is selected from a group consisting of 1 claim 13 , 3 claim 13 , 5 claim 13 , 7 claim 13 , 9 claim 13 , 11 or 13.16. The compound of claim 13 , wherein n is selected from a group consisting of 0 claim 13 , 2 claim 13 , 4 claim 13 , 6 claim 13 , 8 claim 13 , 10 ...

Подробнее
Номер записи: 63
25-02-2016 дата публикации

NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF

Номер: US20160052862A1
Автор: BROOKFIELD Frederick Arthur, COURTNEY Stephen Martin, FROST Lisa Marie, KALISH Vincent Jacob
Принадлежит:

The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer. 3. The compound of wherein X is O claim 2 , NR claim 2 , S claim 2 , S(O) or S(O).4. The compound of wherein X is O.5. The compound of wherein X is NR.6. The compound of wherein X is S.8. A compound of wherein X is O claim 7 , NR claim 7 , S claim 7 , S(O) or S(O).9. A compound of wherein X is O.10. A compound of wherein X is NR.12. A compound of wherein X is S.14. A compound of claim 13 , wherein each R claim 13 , R claim 13 , R claim 13 , R claim 13 , R claim 13 , R claim 13 , R claim 13 , R claim 13 , Rand Ris H.15. A compound of wherein D is selected from the group consisting of alkyl-C(O)— claim 1 , substituted alkyl-C(O)— claim 1 , perhaloalkyl-C(O)— claim 1 , alkenyl-C(O)— claim 1 , substituted alkenyl-C(O)— claim 1 , alkynyl-C(O)— claim 1 , substituted alkynyl-C(O)— claim 1 , aryl-C(O)— claim 1 , substituted aryl-C(O)— claim 1 , heteroaryl-C(O)— claim 1 , substituted heteroaryl-C(O)— claim 1 , heterocyclyl-C(O)—.16. A compound of wherein D is P(O)(O C-Calkyl).18. A compound of wherein Rand Rare independently a substituted C-Calkyl.19. A compound of wherein Rand Rare independently a moiety of the formula C-Calkyl-O—C-Calkyl- or acyl-O—C-Calkyl-.20. A compound of wherein Rand Rare each of the formula CHCH—O—CH— or CHC(O)—O—CH—.21. A compound of wherein D is selected from the group consisting of alkyl-C(O)— claim 18 , substituted alkyl-C(O)— claim 18 , perhaloalkyl-C(O)— claim 18 , alkenyl-C(O)— claim 18 , substituted alkenyl-C(O)— claim 18 , alkynyl-C(O)— claim 18 , substituted alkynyl-C(O)— claim 18 , aryl-C(O)— claim 18 , ...

Подробнее
Номер записи: 64
25-02-2016 дата публикации

Novel phosphatidylalkanols and compositions thereof

Номер: US20160052946A1
Автор: David Wensbo Posaric, Karl-Erik Berquist
Принадлежит: Pethmark AB

The present invention discloses a composition comprising a compound of formula I and a deuterated solvent. The deuterated solvent is miscible with water in any proportion at a temperature of 20 to 25° C. and comprises less than 5% residual 1 H-isotopes. The concentration of the compound of formula I may advantageously be determined by 1 H-QNMR. Methods of production of the composition and salts of compounds of formula I, as well as related analogs and novel reagents and intermediates for the production thereof, are also described.

Подробнее
Номер записи: 65
23-02-2017 дата публикации

WATER-SOLUBLE PROPOFOL DERIVATIVES AND USES THEREOF

Номер: US20170050920A1
Автор: Chen Gang, LI Qingeng, Mao Wei, WANG TAO, Wang Yuanzhong, Wu Tong, Zeng Lingguo
Принадлежит:

The present invention discloses a class of water-soluble propofol derivatives, preparation method thereof, anesthetization method using the same, use thereof as prodrugs and use thereof in the preparation of intravenous anesthetics. The water-soluble propofol derivatives have the general formula (I); wherein X is H or F, Y is F or alkyl substituted by one or more F, n is 1, 2, 3, 4, 5 or 6, W is Wor W; Wis NRR.A or 6. The water soluble propofol derivative according to claim 1 , characterized in that the metal ion is an alkali metal ion claim 1 , an alkaline earth metal ion or a trivalent metal ion.7. The water soluble propofol derivative according to claim 6 , characterized in that the metal ion is a lithium ion claim 6 , a sodium ion or a potassium ion.8. The water soluble propofol derivative according to claim 6 , characterized in that the alkaline earth metal ion is a magnesium ion claim 6 , a zinc ion or a calcium ion.9. The water soluble propofol derivative according to claim 6 , characterized in that the trivalent metal ion is an aluminum ion.11. The water soluble propofol derivative according to claim 10 , characterized in that the alkyl is Calkyl.12. The water soluble propofol derivative according to claim 11 , characterized in that the Calkyl is methyl claim 11 , ethyl claim 11 , propyl claim 11 , isopropyl claim 11 , butyl or isobutyl.13. The water soluble propofol derivative according to claim 10 , characterized in that the cycloalkyl is Ccycloalkyl.14. The water soluble propofol derivative according to claim 13 , characterized in that the Ccycloalkyl is cyclopropyl claim 13 , cyclobutyl claim 13 , cyclopentyl or cyclohexyl.15. The water soluble propofol derivative according to claim 10 , characterized in that R claim 10 , R claim 10 , Rand Rare each independently H claim 10 , methyl claim 10 , ethyl claim 10 , propyl claim 10 , isopropyl claim 10 , butyl claim 10 , isobutyl claim 10 , benzyl claim 10 , cyclopropyl claim 10 , cyclobutyl claim 10 , ...

Подробнее
Номер записи: 66
10-03-2022 дата публикации

Method of Preparing Phosphorus-Containing Flame Retardants and Their Use in Polymer Compositions

Номер: US20220073547A1
Автор: Bonyhady Simon J., He Qingliang, Lee Julia Yue, Sharma Ramesh
Принадлежит: LANXESS CORPORATION

A phosphorus-containing flame retardant is produced by reacting at a reaction temperature a mixture including a metal or suitable metal compound and a stoichiometric excess relative to the metal or suitable metal compound of an unsubstituted or alkyl or aryl substituted phosphonic or pyrophosphonic acid, wherein the phosphonic or pyrophosphonic acid is in a molten state at the reaction temperature. The chemical composition of the resulting flame retardant product leads to excellent flame retardancy and exhibits high thermal stability. The presently disclosed flame retardants are useful, for example, in polymer compositions, particularly thermoplastics processed at high temperatures, over a wide range of applications. 1. A process for producing a phosphorus-containing flame retardant , comprising reacting at a reaction temperature a mixture comprising a metal or suitable metal compound and a stoichiometric excess relative to the metal or suitable metal compound of an unsubstituted or alkyl or aryl substituted phosphonic acid , wherein:{'sub': ['p', 'q'], 'sup': '(+)y', '#text': 'the metal is capable of forming a polycation or the suitable metal compound is represented by the formula MXwhere M is a metal, (+)y represents the charge of the metal cation, y is 2 or higher, X is an anion, and the values for p and q provide a charge balanced metal compound;'}the molar ratio of the unsubstituted or alkyl or aryl substituted phosphonic acid to the metal or suitable metal compound in the mixture is higher than 4:1;the reaction temperature is 105° C. or higher; andthe unsubstituted or alkyl or aryl substituted phosphonic acid is in a molten state at the reaction temperature.2. A process for producing a phosphorus-containing flame retardant , comprising reacting at a reaction temperature a mixture comprising a metal or suitable metal compound and a stoichiometric excess relative to the metal or suitable metal compound of an unsubstituted or alkyl or aryl substituted ...

Подробнее
Номер записи: 67
03-03-2016 дата публикации

PHENOL DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF

Номер: US20160060197A1
Автор: LI Fangqiong, Liu Guoliang, LIU Jianyu, LUO Huadong, LUO Xinfeng, QIN Linlin, REN LEI, Tang Peng Cho, WAN Songlin, Wei Yonggang, YI Shixu
Принадлежит: Sichuan Haisco Pharmaceutical Co., Ltd.

The present invention relates to a phenol derivative and the preparation method and use in medicine thereof, and particular to a phenol derivative represented by general formula (A) or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a cocrystal thereof, a preparation method thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of the central nervous system; wherein the definitions of substituents in general formula (A) are the same as those in the Description. 19. The compound according to claim 1 , or a stereoisomer claim 1 , a solvate claim 1 , a metabolite claim 1 , a prodrug claim 1 , a pharmaceutically acceptable salt claim 1 , or a cocrystal thereof claim 1 ,wherein the salt includes an ammonium salt, a potassium salt, a sodium salt, a calcium salt, a magnesium salt, a tetramethylammonium salt, a tetraethylammonium salt, a tetrapropylammonium salt, a tetrabutylammonium salt, a tetra(isopentyl)ammonium salt, an ethanolamine salt, a diethanolamine salt, a triethanolamine salt, trimethylamine salt, N-methylglucosamine salt, hydrochloride sulfate, phosphate, acetate, trifluoroacetate, fumarate, hemifumarate, maleate, malate, citrate, succinate, benzenesulfonate, or p-toluenesulfonate.22. A pharmaceutical composition claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a compound according to , or a stereoisomer, a solvate, a metabolite, a pharmaceutically acceptable salt, a cocrystal, or a prodrug thereof; and'}one or more pharmaceutically acceptable vehicles and/or excipients.23. Use of the compound according to claim 1 , or a stereoisomer claim 1 , a solvate claim 1 , a metabolite claim 1 , a pharmaceutically acceptable salt claim 1 , a cocrystal claim 1 , or a prodrug thereof claim 1 , for the manufacture of a medicament forinducing and maintaining anesthesia in an animal or a human,facilitating sedation and hypnosis of ...

Подробнее
Номер записи: 68
21-02-2019 дата публикации

SORBITOL, GLUCARIC ACID, AND GLUCONIC ACID BASED FLAME-RETARDANTS

Номер: US20190055472A1
Автор: King Scott B., Kobilka Brandon M., Kuczynski Joseph, Wertz Jason T.
Принадлежит:

A flame-retardant sugar derivative, a process for forming a flame-retardant sugar derivative, and an article of manufacture comprising a flame-retardant sugar derivative are disclosed. The flame-retardant sugar derivative can be synthesized from sorbitol, gluconic acid, or glucaric acid obtained from a bio-based source, and can have at least one phosphoryl or phosphonyl moiety. The process for forming the flame-retardant sugar derivative can include reacting sorbitol, gluconic acid, or glucaric acid and a flame-retardant phosphorus-based molecule to form the flame-retardant sugar derivative. 4. The flame-retardant sugar derivative of claim 1 , wherein Ris a phenyl substituent claim 1 , wherein Ris a phenyl substituent claim 1 , wherein Ris a phenyl substituent claim 1 , wherein Ris a phenyl substituent claim 1 , wherein Ris a phenyl substituent claim 1 , and wherein Ris a phenyl substituent.5. The flame-retardant sugar derivative of claim 1 , wherein Ris an epoxide substituent claim 1 , wherein Ris epoxide substituent claim 1 , wherein Ris an epoxide substituent claim 1 , wherein Ris an epoxide substituent claim 1 , wherein Ris an epoxide substituent claim 1 , and wherein Ris an epoxide substituent.6. The flame-retardant sugar derivative of claim 1 , wherein Ris an allyl substituent claim 1 , wherein Ris allyl substituent claim 1 , wherein Ris an allyl substituent claim 1 , wherein Ris an allyl substituent claim 1 , wherein Ris an allyl substituent claim 1 , and wherein Ris an allyl substituent.7. The flame-retardant sugar derivative of claim 1 , wherein Ris a propylene carbonate substituent claim 1 , wherein Ris a propylene carbonate substituent claim 1 , wherein Ris a propylene carbonate substituent claim 1 , wherein Ris a propylene carbonate substituent claim 1 , wherein Ris a propylene carbonate substituent claim 1 , and wherein Ris a propylene carbonate substituent.8. The flame-retardant sugar derivative of claim 1 , wherein the thioether substituent is ...

Подробнее
Номер записи: 69
02-03-2017 дата публикации

Anti-Viral Compounds

Номер: US20170057981A1
Автор: Chau Jaclyn, Chen Hui-Ju J., DeGoey David A., Halvorsen Geoff T., HARTUNG John, Ide Nathan, Kalthod Vikram, Krueger Allan C., Ku Yi-Yin, Li Tongmei, Marvin Christopher C., Randolph John T., Voight Eric, Wagner Rolf
Принадлежит: AbbVie Inc.

The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. 1. (S)-isopropyl 2-(((S)-(((2R ,3R ,4S ,5R)-4-bromo-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate , or a pharmaceutically acceptable salt thereof.2. Ethyl 2-(((((2R ,3R ,4R ,5R)-4-bromo-4-chloro-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.3. Ethyl 2-(((R)-(((2R ,3R ,4R ,5R)-4-bromo-4-chloro-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.4. Ethyl 2-(((S)-(((2R ,3R ,4R ,5R)-4-bromo-4-chloro-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1 (2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.5. Ethyl 2-(((S)-(((2R ,3R ,4S ,5R)-4-bromo-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate , or a pharmaceutically acceptable salt thereof.6. A method for treating HCV claim 1 , comprising administering a compound or salt of to an HCV patient.7. A method for treating HCV claim 2 , comprising administering a compound or salt of to an HCV patient.8. A method for treating HCV claim 3 , comprising administering a compound or salt of to an HCV patient.9. A method for treating HCV claim 4 , comprising administering a compound or salt of to an HCV patient.10. A method for treating HCV claim 5 , comprising administering a compound or salt of to an HCV patient.11. A pharmaceutical composition comprising a ...

Подробнее
Номер записи: 70
02-03-2017 дата публикации

Method for reducing the chlorine content of organobisphosphites

Номер: US20170057985A1
Автор: Katrin Marie Dyballa, Robert Franke
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to a universally usable process for reducing the chlorine content of organobisphosphites.

Подробнее
Номер записи: 71
04-03-2021 дата публикации

Methods of isolating phenols from phenol-containing media

Номер: US20210061743A1
Автор: Bradley Bolling, Danielle Voss, Matthew Dorris, Yuwei WU
Принадлежит: WISCONSIN ALUMNI RESEARCH FOUNDATION

Methods of isolating phenols from phenol-containing media. The methods include combining a phospholipid-containing composition with the phenol-containing medium to generate a combined medium, incubating the combined medium to precipitate phenols in the combined medium and thereby form a phenol precipitate phase and a phenol-depleted phase, and separating the phenol precipitate phase and the phenol-depleted phase. The methods can further include extracting phenols from the separated phenol precipitate phase. The extracting can include mixing the separated phenol precipitate phase with an extraction solvent to solubilize in the extraction solvent at least a portion of the phenols originally present in the phenol precipitate phase.

Подробнее
Номер записи: 72
22-05-2014 дата публикации

CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS

Номер: US20140141074A1
Автор: HARLAND Henri, Sampalis Fotini
Принадлежит: Acasti Pharma, Inc.

The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition. 151.-. (canceled)53. The method of claim 52 , wherein the composition is contained in a capsule.54. The method of claim 52 , wherein the composition further comprises an antioxidant.55. The method of claim 54 , wherein the antioxidant is astaxanthin.56. The method of claim 52 , wherein the concentrated therapeutic phospholipid composition is derived from krill.57. The method of claim 52 , wherein the composition further comprises triglycerides at a concentration of below about 5%.59. The method of claim 58 , wherein the composition is contained in a capsule.60. The method of claim 58 , wherein the composition further comprises an antioxidant.61. The method of claim 60 , wherein the antioxidant is astaxanthin.62. The method of claim 58 , wherein the concentrated therapeutic phospholipid composition is derived from krill.63. The method of claim 58 , wherein the composition further comprises triglycerides at a concentration of below about 5%.64. The method of claim 58 , wherein the hypertriglyceridemia is moderate hypertriglyceridemia.65. The method of claim 58 , wherein the method comprises reducing fasting plasma levels of low-density lipoprotein cholesterol (LDL-C).66. The method of claim 58 , wherein the method comprises increasing fasting plasma levels of high-density lipoprotein cholesterol (HDL-C).67. The method of claim 65 , wherein the method comprises increasing fasting plasma levels of high-density lipoprotein cholesterol (HDL-C). This application is a continuation of U.S. application Ser. No. 12/915,724, filed Oct. 29, 2010, which claims the benefit of Provisional ...

Подробнее
Номер записи: 73
10-03-2016 дата публикации

IMMOBILIZED CATALYTICALLY ACTIVE COMPOSITION FOR HYDROFORMYLATION OF OLEFIN-CONTAINING MIXTURES

Номер: US20160068459A1
Автор: Becker Marc, DEBUSCHEWITZ Jonas, DYBALLA Katrin Marie, Franke Robert, HAHN Hanna, HAUMANN Marco, KAFTAN Andre, LAURIN Mathias, LIBUDA Joerg, SCHOENWEIZ Andreas, WALTER Simon, Wasserscheid Peter, WOELFEL Rene
Принадлежит: EVONIK DEGUSSA GmbH

A composition and the use of said composition as catalytically active composition in processes for synthesis of chemical compounds, especially the hydroformylation of olefinically unsaturated hydrocarbon mixtures. 1. A composition comprising:a) at least one inert porous support material;b) at least one metal selected from the eighth transition group of the Periodic Table of the Elements;c) at least one organic phosphorus compound; andd) at least one high-boiling liquid on the inert porous support material, having a lower vapour pressure than 0.074 MPa at 100° C. and 1.0 MPa,wherein the composition is free of ionic liquids.2. The composition as claimed in claim 1 , i) mean pore diameter within a range from 1 to 430 nm;', 'ii) pore volume within a range from 0.1 to 2 ml/g; and', {'sup': '2', 'iii) BET surface area within a range from 10 to 2050 m/g.'}], 'wherein the inert porous support material has the following material properties3. The composition as claimed in claim 1 ,wherein the organic phosphorus compounds are phosphines, phosphites and/or phosphoramidites.5. The composition as claimed in claim 1 , wherein the high-boiling liquid is formed in situ during use in a process for chemical synthesis.6. The composition as claimed in claim 5 , wherein the high-boiling liquid is formed in situ during the hydroformylation of olefin-containing hydrocarbon mixtures.7. A process for hydroformylating olefin-containing hydrocarbon mixtures claim 5 , comprising:a) introducing an olefin-containing hydrocarbon mixture into a reaction mixture,b) introducing an inert porous support material into the reaction mixture,c) introducing at least one metal selected from the group consisting of cobalt, rhodium, iridium and ruthenium into the reaction mixture,d) introducing at least one organic phosphorus compound selected from the group consisting of phosphines, phosphites and phosphoramidites into the reaction mixture,e) introducing an aldol compound which is not part of the olefin- ...

Подробнее
Номер записи: 74
10-03-2016 дата публикации

NOVEL COMPOUND AND RESIN COMPOSITION CONTAINING THE SAME

Номер: US20160068553A1
Автор: Komuro Takeshi, Matsuda Katsuhiro, MIURA Toshinari
Принадлежит:

To provide a compound which can demonstrate flame retardancy equal to or higher than V-1 of the UL94 standard by adding a flame retardant to resin containing aromatic polyester and styrene polymer. 3. The compound according to claim 2 , wherein the compound is plant derived.4. A flame retardant comprising the compound according to .5. A resin composition comprising resin and the flame retardant according to .6. A resin composition containing aromatic polyester claim 4 , a styrene polymer claim 4 , a dripping inhibitor claim 4 , and the flame retardant according to claim 4 , whereina content of the aromatic polyester is 40 wt % or more and 90 wt % or less when a total weight of the resin composition is 100 wt %,a content of the styrene polymer is 5 wt % or more and 30 wt % or less when the total weight of the resin composition is 100 wt %,a content of the dripping inhibitor is 0.1 wt % or more and 1.0 wt % or less when the total weight of the resin composition is 100 wt %, anda content of the flame retardant is 10 wt % or more and 25 wt % or less when the total weight of the flame retardant composition is 100 wt %.7. The resin composition according to claim 6 , wherein the aromatic polyester is aromatic polycarbonate.8. The resin composition according to claim 6 , wherein the styrene polymer is an acrylonitrile-butadiene-styrene copolymer or an acrylonitrile-styrene copolymer.9. The resin composition according to claim 6 , wherein the dripping inhibitor is a compound containing polytetrafluoroethylene.10. A molded article claim 6 , which is obtained by molding the resin composition according to .11. The molded article according to claim 10 , wherein the aromatic polyester and the styrene polymer are obtained from recovered resin.12. The molded article according to claim 10 , wherein flame retardancy is equal to or higher than V-1 in a V test of UL94 standard.14. A resin composition comprising resin and a flame retardant claim 3 , wherein the frame retardant is the ...

Подробнее
Номер записи: 75
11-03-2021 дата публикации

3,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE-BASED MONOPHOSPHINE LIGAND, INTERMEDATES TEHREOF, PREPARATION METHOD AND USE OF THE SAME

Номер: US20210070789A1
Автор: Lin Xufeng, SHAN Huanyu, ZHOU Qiaoxia
Принадлежит:

Provided are a 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based monophosphine ligand and intermediates thereof, and preparation methods and uses of the same. The monophosphine ligand is a compound represented by formula I or formula I′, or an enantiomer, a raceme or a diastereoisomer thereof, including phosphonite ligands, phosphite ligands, phosphoramidite ester ligands, phosphoric acid and phosphonic amide. The monophosphine ligand is prepared with a known 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-7,7′-diol derivative as a raw material through a scheme in which the compound presented by formula II acts as an intermediate. The present disclosure provides a novel monophosphine ligand, which can be used as a ligand in a metal-catalysed organic reactions or in directly catalyzing an organic reaction, especially as a chiral monophosphine ligand widely used in many chiral catalytic reactions such as asymmetric addition, asymmetric hydrogenation, asymmetric coupling, and asymmetric allyl alkylation, having economic practicality and industrial application prospects. 910.-. (canceled) The invention relates to the technical field of organic chemistry, and relates to a novel 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based monophosphine ligand, intermediates thereof, and a preparation method and a use of the same. Such a monophosphine ligand can be used in a metal-catalysed coupling reaction or an asymmetric reaction, or in directly catalyzing an organic reaction.Asymmetric catalytic synthesis is one of the most intensive research areas in modern synthetic chemistry. This technique uses the most direct and effective chemical method for obtaining chiral molecules. It has advantages such as chiral proliferation, high enantio-selectivity, economy, and ease industrialization. It is challenging in the field of synthetic chemistry to perform efficient and highly selective asymmetric catalytic reactions, and the pivotal scientific issue thereof is to develop or discover new and ...

Подробнее
Номер записи: 76
12-03-2015 дата публикации

PURIFICATION PROCESS

Номер: US20150073169A1
Автор: Miller Glenn A.
Принадлежит: DOW TECHNOLOGY INVESTMENTS LLC

A process for reducing the level of contaminant metals in ligands used in the preparation of catalysts is disclosed. 1. A process comprising:(A) contacting a trivalent phosphorous ligand, a contaminant metal, a first solvent, a polar complexing agent and a second solvent to form a mixture,(B) obtaining a first phase comprising the ligand and the first solvent, and(C) obtaining a second phase comprising the second solvent and at least one complex of the contaminant metal and the polar complexing agent, and(D) separating the two phases.2. The process of wherein the two phases are predominantly in the liquid phase.3. The process of wherein the second solvent comprises water.4. The process of wherein the contaminant metal comprises iron.5. The process of wherein the polar complexing agent comprises ethylenediamine tetraacetic acid and alkali metal salts thereof.6. The process of conducted under conditions such that the concentration of metal salt in the presence of the ligand prior to step (A) is higher than the concentration of metal salt in first phase after step (D).7. The process of wherein the trivalent phosphorous ligand comprises at least one bisphosphite.8. The process of wherein the trivalent phosphorous ligand comprises at least one aryl or alkyl phosphine. This application claims priority from provisional application Ser. No. 61/541,291, filed Sep. 30, 2011, which is incorporated herein by reference in its entirety.The invention relates to the purification of ligands that can be used for the preparation of catalysts.Metal complex catalysts are a common class of catalysts and are used, for example, in commercial scale hydroformylation, hydrocyanation, olefin isomerization, cyclopropanation, and hydrogenation reactions. The presence of certain metals (primarily transition metals, e.g., iron) in hydroformylation systems is detrimental in that these contaminant metals can promote heavies formation or other side reactions.The source of contaminant metals, such as ...

Подробнее
Номер записи: 77
29-05-2014 дата публикации

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

Номер: US20140148415A1
Автор: David Olivier, Dumortier Thomas, Looby Michael, Schmouder Robert
Принадлежит: NOVARTIS AG

S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage. 2. The method according to claim 1 , wherein the autoimmune disease or disorder is multiple sclerosis.3. The method according to claim 1 , wherein the autoimmune disease or disorder is relapse remitting multiple sclerosis or primary progressive multiple sclerosis.4. The method according to claim 1 , wherein during the initial period of treatment the dosage is increased stepwise up to the standard daily dosage of said S1P receptor modulator or agonist.5. The method according to claim 1 , wherein the daily dosage during the initial period of treatment is up to 10 fold less than the standard daily dosage.6. The method according to claim 1 , wherein the initial period of treatment is selected from the group consisting of: 4 to 12 days claim 1 , 5 to 14 days claim 1 , up to 10 days claim 1 , 7 to 10 days claim 1 , 9 days claim 1 , 8 days claim 1 , 7 days claim 1 , 6 days claim 1 , 5 days or 4 days.7. The method according to claim 1 , in a patient at risk of cardiac side effects or heart failure.8. The method according to claim 1 , while limiting claim 1 , reducing or preventing the occurrence of symptoms including dizziness claim 1 , fatigue and heart palpitations.1028. The method according to claim claim 1 , wherein the initial treatment period is 6 to 14 days.1128. The method according to claim claim 1 , wherein the standard daily dosage is about 0.5 mg or less.1211. The S1P receptor modulator or agonist for use according to any one of to claims 1 , wherein said modulator or agonist is administered to patients having undergone an interruption or treatment holiday of S1P receptor modulator or agonist therapy. The present invention relates to a dosage regimen of a S1P receptor modulator or agonist. More specifically, the present invention relates to a dosage regimen for the treatment of ...

Подробнее
Номер записи: 78
17-03-2016 дата публикации

METHOD OF IMPROVING GRASS QUALITY

Номер: US20160073637A1
Автор: HANRAHAN Richard, NORTON Lawrence H., SPAK David R.
Принадлежит:

The invention relates to a method of improving grass quality comprising applying an effective amount of a composition containing a phthalocyanine to the grass in the substantial absence of phosphorous acid, monoalkyl esters of phosphorous acid, or salts thereof. 1. A wettable powder composition for improving grass comprising from 1% to 95% by weight of a phthalocyanine on a solid support , from 0 to 5% by weight of a wetting agent , from 3 to 10% by weight of a dispersant , and wherein the composition does not include phosphorous acid or a salt thereof or a monoalkyl ester of phosphorous acid or a salt thereof.2. The wettable powder composition of claim 1 , wherein said phthalocyanine is a copper phthalocyanine.3. The wettable powder composition of further comprising one or more fungicides claim 1 , acaricides claim 1 , and/or insecticides.4. The wettable powder composition of claim 1 , wherein said phthalocyanine is selected from the group consisting of Pigment Blue 16 claim 1 , Vat Blue 29 claim 1 , Pigment Blue 15 claim 1 , Heliogen Green GG claim 1 , Ingrain Blue 14 claim 1 , Ingrain Blue 5 claim 1 , Ingrain Blue 1 claim 1 , Pigment Green 37 claim 1 , and Pigment Green 7.5. The wettable powder composition of claim 1 , wherein said phthalocyanine is selected from the group consisting of Pigment Blue 15 and Pigment Green 7.6. The wettable powder composition of further comprising one or more stabilizers and/or additives.7. The method of claim 1 , wherein said composition comprises from about 45% to 55% by weight of a copper phthalocyanine.8. A method of improving grass quality comprising applying an effective amount of a composition containing a phthalocyanine and water to a grass claim 1 , wherein(i) the composition does not include phosphorous acid or a salt thereof or a monoalkyl ester of phosphorous acid or a salt thereof; and(ii) 0.001 to 10 kg per hectare of said phthalocyanine is applied.9. The method of claim 8 , wherein said composition does not include a ...

Подробнее
Номер записи: 79
07-03-2019 дата публикации

ANTI-INFLAMMATORY PROPERTIES OF MARINE LIPID COMPOSITIONS

Номер: US20190070203A1
Автор: Banno Sebastiano, Bruheim Inge, Fuglseth Erik, Griinari Mikko, SAEBO Per Christian
Принадлежит:

Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines. 126-. (canceled)28. The gel capsule of claim 27 , wherein said lipid composition has a lysophospholipid content of from 15% to 30% w/w of said composition.29. The gel capsule of wherein said mixture of phospholipids has a ratio of EPA/DHA residues ranging from 1:1 to 4:1.30. The gel capsule of claim 27 , wherein said mixture of phospholipids having a ratio of EPA/DHA residues ranging from 2:1 to 4:1.31. The gel capsule of claim 27 , wherein said lipid composition further comprises triglycerides.32. The gel capsule of claim 27 , wherein said mixture of phospholipid molecules is characterized in comprising at least 15% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2.33. The gel capsule of claim 27 , wherein said mixture of phospholipid molecules is characterized in comprising at least 20% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2.35. The gel capsule of claim 34 , wherein said lipid composition has a lysophospholipid content of from 15% to 30% w/w of said composition.36. The gel capsule of claim 34 , wherein said mixture of phospholipid molecules has a ratio of EPA/DHA residues ranging from 1:1 to 4:1.37. The gel capsule of claim 34 , wherein said mixture of phospholipids having a ratio of EPA/DHA residues ranging from 2:1 to 4:1.38. The gel capsule of claim 34 , wherein said lipid composition further comprises triglycerides.40. The gel capsule of claim 39 , wherein said mixture of phospholipids has a ratio of EPA/DHA residues ranging from 1:1 to 4:1.41. The gel capsule of claim 39 , wherein said mixture of phospholipids having a ratio of EPA/DHA ranging from 2:1 to 4:1.42. The gel capsule ...

Подробнее
Номер записи: 80
19-03-2015 дата публикации

Multi-element Standard for Nuclear Magnetic Resonance Spectroscopy

Номер: US20150077104A1
Автор: Diehl Bernd Willi Karl-Heinz
Принадлежит:

Organic compounds which contain nitrogen, fluorine, and phosphorus atoms together with carbon atoms and hydrogen atoms and which can be used as a multi-element standard for H—, C—, N—, F—, and P nuclear magnetic resonance spectroscopy. Also, a nuclear magnetic resonance spectroscopy method, preferably a quantitative nuclear magnetic resonance spectroscopy method, using said compounds and a method for qualitatively and/or quantitatively determining an analyte using such a nuclear magnetic resonance spectroscopy method. 117-. (canceled)1918. The use according to , wherein the benzene ring carries precisely two hydrogen atoms as substituents.20. The use according to claim 19 , wherein the two hydrogen atoms are meta to one another on the benzene ring.21. The use according to claim 18 , wherein at least one hydrogen atom on the benzene ring is ortho to at least one CFsubstituent or CHsubstituent.22. The use according to claim 18 , wherein at least two hydrogen atoms on the benzene ring are ortho to at least one CFsubstituent or CHsubstituent.23. The use according to claim 18 , wherein at least two hydrogen atoms on the benzene ring are ortho to at least one substituent selected from —NOand —C(═O)OR.24. The use as claimed in claim 18 , wherein the benzene ring carries only one hydrogen atom as substituent claim 18 , and the hydrogen atom on the benzene ring is preferably ortho to at least one CFsubstituent or CHsubstituent.25. The use according to claim 18 , wherein claim 18 , in a H nuclear magnetic resonance spectroscopy claim 18 , with the chemical shift of tetramethylsilane set as 0 ppm claim 18 , the chemical shift δ of at least one hydrogen atom on the benzene ring is at least 8 ppm.26. The use as claimed in claim 25 , wherein the spin-lattice relaxation time Tof the at least one hydrogen atom having the chemical shift of at least 8 ppm is not more than 5 s.27. The use according to claim 25 , wherein the chemical shift of two hydrogen atoms on the benzene ring is ...

Подробнее
Номер записи: 81
17-03-2016 дата публикации

METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS

Номер: US20160075634A1
Автор: GONZALEZ Miguel, Heckhoff Stefan, Oniciu Daniela Carmen, Oswald Benoit, PEER Andreas, Rebmann Peter, Sauter Patrik
Принадлежит:

The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides. 2. The method of claim 1 , wherein R is a methyl group.3. A method for synthesizing N-palmitoyl-D-erythro-sphingosine claim 1 , comprising the steps of:a) allowing (1R,2R,5R)-(+)-2-hydroxy-3-pinanone to react with ethylglycinate under conditions effective to yield (1R,2R,5R)-ethyl-((2-hydroxypinan-3-ylene)amino)acetate;b) allowing (1R,2R,5R)-ethyl-((2-hydroxypinan-3-ylene)amino)acetate (Compound IIIb) to react with 2-(E)-hexadecen-1-al in the presence of chlorotitanium triisopropoxyde and triethylamine under conditions effective to yield one or both of (2S,3R,E)-ethyl 3-hydroxy-2-((E)-((1S,2S,5S)-2-hydroxy-2,6,6-trimethylbicyclo[3.1.1]heptan-3-ylidene)amino)octadec-4-enoate and (2S,3R,E)-isopropyl 3-hydroxy-2-((E)-((1S,2S,5S)-2-hydroxy-2,6,6-trimethylbicyclo[3.1.1]heptan-3-ylidene)amino)octadec-4-enoate;c) allowing the one or both of (2S,3R,E)-ethyl 3-hydroxy-2-((E)-((1S,2S,5S)-2-hydroxy-2,6,6-trimethylbicyclo[3.1.1]heptan-3-ylidene)amino)octadec-4-enoate and (2S,3R,E)-isopropyl 3-hydroxy-2-((E)-((1S,2S,5S)-2-hydroxy-2,6,6-trimethylbicyclo[3.1.1]heptan-3-ylidene)amino)octadec-4-enoate to react with hydrochloric acid under conditions effective to yield one or both of (2R,3R,E)-ethyl 2-amino-3-hydroxyoctadec-4-enoate and (2R,3R,E)-propyl 2-amino-3-hydroxyoctadec-4-enoate;d) allowing the one or both of (2R,3R,E)-ethyl 2-amino-3-hydroxyoctadec-4-enoate and (2R,3R,E)-propyl 2-amino-3-hydroxyoctadec-4-enoate to react with sodium borohydride under conditions effective to yield D-erythro-sphingosine; ande) allowing D-erythro-sphingosine to react with palmitic acid under conditions effective to yield N-palmitoyl-D-erythro-sphingosine.4. A method for synthesizing an N-acyl-D- ...

Подробнее
Номер записи: 82
24-03-2022 дата публикации

DIPHOSPHITES HAVING AN OPEN, 2,4-METHYLATED OUTER UNIT

Номер: US20220089623A1
Автор: BRÄCHER Alexander, Franke Robert, Fridag Dirk, Knossalla Johannes, SALE Anna Chiara
Принадлежит: EVONIK OPERATIONS GMBH

Diphosphites having an open, 2,4-methylated outer unit and use thereof in hydroformylation. 2. Compound according to claim 1 ,{'sup': 1', '3, 'sub': 1', '12, 'where R, Rare selected from: —H, —(C-C)-alkyl.'}3. Compound according to claim 1 ,{'sup': 1', '3, 'sub': 1', '12, 'where R, Rare —(C-C)-alkyl.'}4. Compound according to claim 1 ,{'sup': 1', '3, 'where R, Rare the same radical.'}5. Compound according to claim 1 ,{'sup': 2', '4, 'sub': 1', '12, 'where R, Rare selected from: —H, —O—(C-C) alkyl.'}6. Compound according to claim 1 ,{'sup': 2', '4, 'sub': 1', '12, 'wherein R, Rare —O—(C-C)-alkyl.'}7. Compound according to claim 1 ,{'sup': 2', '4, 'where R, Rare the same radical.'}8. Compound according to claim 1 ,{'sup': 1', '2', '3', '4, 'sub': '3', 'where R, R, R, Rare not all simultaneously —CH.'}10. Use of a compound according to in a ligand-metal complex for catalysis of a hydroformylation reaction.11. Process comprising the process steps of:a) initially charging an olefin,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'b) adding a compound according to and a substance containing a metal selected from: Rh, Ru, Co, Ir,'}{'sub': '2', 'c) supplying Hand CO,'}d) heating the reaction mixture from steps a) to c), with conversion of the olefin to an aldehyde. The invention relates to diphosphites having an open, 2,4-methylated outer unit and use thereof in hydroformylation.Phosphorus-containing compounds play a crucial role as ligands in a multitude of reactions, e.g. in hydrogenation, in hydrocyanation and also in hydroformylation.The reactions between olefin compounds, carbon monoxide and hydrogen in the presence of a catalyst to give the aldehydes with one carbon atom more are known as hydroformylation or the oxo process. In these reactions, compounds of the transition metals of group VIII of the Periodic Table of the Elements are frequently employed as catalysts. Known ligands are, for example, compounds from the phosphine, phosphite and phosphorite classes, ...

Подробнее
Номер записи: 83
07-03-2019 дата публикации

Novel phosphorus compounds, synthesis method thereof, and polycarbonate resin composition including them

Номер: US20190071566A1
Автор: Jinhwan Kim, Sang-Won Park, Soo-jung Kang, VO Thi Hai
Принадлежит: Sungkyunkwan University Research and Business Foundation

The present disclosure relates to a phosphorus compound represented by the following Chemical Formula 1. In the above Chemical Formula 1, Ar is aryl and R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently H, substitutable linear or branched C 1 -C 20 alkyl and substitutable C 6 -C 20 aryl, the aryl includes a member selected from the group consisting of phenyl, biphenyl, naphthalene, fluorene, anthracene, phenanthrene, pyrene, fluoranthen, chrysene, benzofluoranthen, perylene, quinoline, indenoanthracene, indenophenanthrene, hydroanthracene, dibenzothiophen, dibenzofuran, and combinations thereof, and the substitution is substitution with C 1 -C 6 alkyl or C 6 -C 20 aryl, but may not be limited thereto.

Подробнее
Номер записи: 84
19-03-2015 дата публикации

LIQUID FORMULATIONS

Номер: US20150080347A9
Автор: Georgousis Vivian, Tong Wei-Qin
Принадлежит: NOVARTIS AG

Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. 1. A concentrate for dilution comprising a S1P receptor modulator or agonist or a pharmaceutically acceptable salt thereof , and propylene glycol.2. A concentrate according to claim 1 , comprising in addition glycerin.4. A concentrate according to comprising a S1P receptor modulator or agonist selected from 2-amino-2-[2-(4-octylphenylethyl)]propane-1 claim 1 ,3-diol claim 1 , 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1 claim 1 ,3-propane-diol claim 1 , or a corresponding phosphate thereof claim 1 , and 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid claim 1 , or a pharmaceutically acceptable salt thereof.5. A concentrate according to comprising glycerin and propylene glycol in a ratio of about 5:95 to about 25:75.6. A concentrate according to which is diluted with a vehicle in a ratio of from 1:1 to more than 1:10 prior to administration.7. A pharmaceutical solution comprising a concentrate according to diluted with a vehicle in a ratio of from 1:1 to more than 1:10.8. A pharmaceutical solution according to for oral administration.9. A method of treating a subject in need of immunosuppression claim 1 , comprising administering to the subject a concentrate according to which is diluted with a vehicle in a ratio of from 1:1 to more than 1:10 prior to administration. The present invention relates to pharmaceutical compositions comprising a sphingosine-1 phosphate receptor modulator or agonist or a pharmaceutically acceptable salt thereof.Sphingosine-1 phosphate (hereinafter “S1P”) is a natural serum lipid. Presently there are eight known S1P receptors, namely S1P1 to S1P8. S1P receptor modulators or agonists are typically sphingosine analogues, such as 2- ...

Подробнее
Номер записи: 85
19-03-2015 дата публикации

ARYLFLUOROPHOSPHATE INHIBITORS OF INTESTINAL APICAL MEMBRANE SODIUM/PHOSPHATE CO-TRANSPORT

Номер: US20150080597A1
Автор: Peerce Brian, Slomowitz Larry
Принадлежит:

The present invention is directed to fluorophosphates, and pharmaceutical compositions thereof, which are inhibitors of intestinal apical sodium/phosphate co-transport and are useful in the treatment of hyperphosphatemia, in reducing blood phosphate levels, and in treating hypertension. 235.-. (canceled) This application claims the benefit of the filing date of U.S. Provisional Application No. 61/310,902, which was filed Mar. 5, 2010.This invention relates to hydrophilic aryl fluorophosphates that act to inhibit intestinal apical membrane Na-mediated phosphate co-transport, effective treatments to reduce blood phosphate, methods of treating hyperphosphatemia, and methods of making inhibitors.Secondary hyperparathyroidism is a common and severe complication of chronic renal failure (CRF) resulting in renal osteodystrophy, hypertension, metabolic acidosis, and contributing to cardiac disease. Hyperphosphatemia due to decreased renal phosphate excretion is thought to contribute to secondary hyperparathyroidism in patients with chronic renal insufficiency. Recently, it has been established that decreasing the phosphate load can reduce secondary hyperparathyroidism and possibly preserve renal function.In mammals, intestinal phosphate absorption occurs at the brush border membrane in the proximal intestine (duodenum and jejunum). Phosphate absorption has an active component and a passive component. Active uptake of phosphate is coupled to Na uptake down its electrochemical potential gradient by the Na/phosphate cotransporter. The active component of phosphate absorption is regulated by dietary phosphorus and serum 1,25 dihydroxyvitamin D. Changes in dietary phosphorus have been reported to alter expression of NaPi II b in the intestine. Na-independent phosphate uptake occurs by an unknown mechanism down its electrochemical potential gradient. The mechanism of phosphate transport across the intestinal basolateral membrane has not been definedChalcones are a class of ...

Подробнее
Номер записи: 86
18-03-2021 дата публикации

COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS

Номер: US20210079036A1
Автор: Seifert Cole
Принадлежит: GAP Peptides LLC

The disclosure relates to chemical compositions that can include anchor molecules for chemical synthesis. GAP anchor molecules can include GAP constituents, linker constituents, and spacer constituents. Anchor molecules can be used to synthetically manufacture peptides. A novel method of solution-phase peptide synthesis is also disclosed that utilizes novel group-assisted purification protecting groups to facilitate efficient, scalable chemistry to synthetically manufacture peptides. 1. A chemical composition comprising a GAP constituent , a spacer constituent , and a linker constituent , wherein the spacer constituent is disposed between the GAP constituent and the linker constituent.2. The composition of claim 1 , wherein the GAP constituent comprises a phosphine oxide moiety and at least one aromatic moiety.6. The composition of claim 1 , wherein the linker constituent is selected from the group consisting of: 4-(hydroxymethyl)phenoxyacetyl (“HMPA”) claim 1 , 4-(hydroxymethyl)phenoxybutanoyl (“HMPB”) claim 1 , 4-(hydroxymethyl)benzoyl (“HMB”) claim 1 , 4-(mercaptomethyl)benzoyl (“MMB”) claim 1 , 4-(mercaptomethyl)phenoxyacetyl (“MMPA”) claim 1 , 4-(aminomethyl)phenoxyacetyl (“AMPA”) claim 1 , 4-(3 claim 1 ,3-dimethyl-3-hydroxypropyl)phenoxyacetyl (“DMPPA”) claim 1 , 2-(4-(amino(2 claim 1 ,4-dimethoxyphenyl)methyl)phenoxy)acetyl (“Rink Amide”) claim 1 , 4-((9-amino-9H-xanthen-3-yl)oxy)butanoyl (“Xanthenyl”) claim 1 , 5-(5-amino-10 claim 1 ,11-dihydro-5H-dibenzo[a claim 1 ,d][7]annulen-3-yl)pentanoyl (“TCA”) claim 1 , and 3-(4-(chloro(2-chlorophenyl)(phenyl)methyl)phenyl)propanoyl (“2-Chlorotrityl”).15. The composition of claim 12 , wherein L is selected from the group consisting of: 4-(hydroxymethyl)phenoxyacetyl (“HMPA”) claim 12 , 4-(hydroxymethyl)phenoxybutanoyl (“HMPB”) claim 12 , 4-(hydroxymethyl)benzoyl (“HMB”) claim 12 , 4-(mercaptomethyl)benzoyl (“MMB”) claim 12 , 4-(mercaptomethyl)phenoxyacetyl (“MMPA”) claim 12 , 4-(aminomethyl)phenoxyacetyl (“AMPA”) ...

Подробнее
Номер записи: 87
24-03-2016 дата публикации

EXTRACTION SOLVENT CONTROL FOR REDUCING STABLE EMULSIONS

Номер: US20160083406A1
Автор: AKI Sudhir N.V.K., Chao Tseng H., III William J., TENN, Vos Thomas E.
Принадлежит: INVISTA NORTH AMERICA S.A R.L.

Disclosed herein are methods for recovering diphosphonite-containing compounds from mixtures comprising organic mononitriles and organic dinitriles, using liquid-liquid extraction. Also disclosed are treatments to enhance extractability of the diphosphonite-containing compounds. 1. A process for recovering diphosphonite-containing compounds from a feed mixture comprising diphosphonite-containing compounds , organic mononitriles , organic dinitriles and a Lewis acid in a multistage countercurrent liquid-liquid extractor with extraction solvent comprising aliphatic hydrocarbon , cycloaliphatic hydrocarbon or a mixture of aliphatic and cycloaliphatic hydrocarbon , said process comprising:a) flowing the feed mixture to the first stage of the multistage countercurrent liquid-liquid extractor; and wherein the first stage of the multistage countercurrent liquid-liquid extractor comprises a mixing section and a settling section, wherein the mixing section provides a mixed phase comprising a light phase and a heavy phase, wherein a light phase separates from a heavy phase in the settling section, wherein a mixed phase comprising a heavy phase, light phase is present in the settling section between the light phase and the heavy phase, wherein the light phase comprises extraction solvent and extracted diphosphonite-containing compounds, wherein the heavy phase comprises organic mononitriles and organic dinitriles, wherein at least a portion of the light phase is withdrawn from the settling section and treated to recover diphosphonite-containing compounds extracted into the light phase, wherein at least a portion of the heavy phase is passed to the second stage of the multistage countercurrent liquid-liquid extractor, and wherein the process further comprises at least one of the following additional steps:', '(i) withdrawing a portion of the heavy phase from the settling section of the first stage of the multistage countercurrent liquid-liquid extractor and recycling the ...

Подробнее
Номер записи: 88
24-03-2016 дата публикации

PHOSPHOROUS CONTAINING FLAME RETARDANTS

Номер: US20160083500A1
Автор: Balbo Block Marco, FERBITS Jens, Fleckenstein Christoph, Hupka Birgit
Принадлежит: BASF SE

The present invention relates to a phosphorus containing polyol, obtainable or obtained by a process comprising the reaction of at least one polyol with a phosphorus containing compound of the general formula (I) as defined herein, as well as the process for preparing a phosphorus containing polyol, comprising the reaction of at least one polyol with a phosphorus containing compound of the general formula (I). Furthermore, the present invention relates to the use of a phosphorus containing polyol as disclosed herein as a flame retardant, to a process for the preparation of a polyurethane and the polyurethane as such. 2. The phosphorous-comprising polyol according to claim 1 , wherein the phosphorus is present in a form of phosphate or a phosphinate group.3. The phosphorous-comprising polyol according to claim 1 , which has an OH-functionality of from 0 to 8.4. The phosphorous-comprising polyol according to claim 1 , which has a phosphorous content of from 7 to 12% by weight based on a total weight of the phosphorous-comprising polyol.5. The phosphorous-comprising polyol according to claim 1 , which has a molecular weight of from 100 to 700 g/mol.7. A flame retardant claim 1 , comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the phosphorous-comprising polyol according to .'}8. A process for preparing a polyurethane claim 1 , the process comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'introducing the phosphorous-comprising polyol according to into the process.'}9. A process for preparing a polyurethane claim 1 , the process comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting at least one isocyanate (a), at least one polyol (b) and at least one phosphorous-comprising polyol according to .'}10. The process according to claim 9 , wherein the at least one phosphorous-comprising polyol is used in an amount of 1 to 30% of a total of all polyols.11. A polyurethane claim 9 , obtained by the process according to .12. The polyurethane ...

Подробнее
Номер записи: 89
25-03-2021 дата публикации

IONIC LIQUID CONTAINING DIVALENT CATION AND MONOVALENT ANION AND LUBRICANT COMPOSITION COMPRISING SAME

Номер: US20210087490A1
Автор: HWANG Sun Ae, Shim Yu Na, Shin Sang Hye, Song Ha Na
Принадлежит:

Disclosed are an ionic liquid, having wear resistance maintained at low temperatures and containing a divalent cation including at least one of bis(ammonium) and bis(phosphonium) and a monovalent anion including at least one of sulfonate and phosphate, and a lubricant composition including the ionic liquid. 1. An ionic liquid , comprising:a divalent cation comprising at least one of bis(ammonium) and bis(phosphonium); anda monovalent anion comprising at least one of sulfonate and phosphate.3. The ionic liquid of claim 2 , wherein in Chemical Formula 1 claim 2 , Rand Rare each independently (C1-C20)alkyl claim 2 , (C2-C20)alkenyl claim 2 , (C2-C20)alkynyl claim 2 , (C3-C7)cycloalkyl claim 2 , (C5-C20)heteroalkyl claim 2 , (C6-C20)aryl claim 2 , (C6-C20)ar(C1-C10)alkyl claim 2 , (C1-C10)alkoxy claim 2 , (C6-C20)aryloxy claim 2 , (C1-C10)alkoxycarbonyl(C1-C20)alkyl claim 2 , or (C1-C20)alkylcarbonyl.4. The ionic liquid of claim 2 , wherein in Chemical Formula 1 claim 2 , Rand Rare each independently (C1-C8)alkyl claim 2 , and Ris (CH) claim 2 , where 1≤n≤12.6. The ionic liquid of claim 5 , wherein in Chemical Formula 2 claim 5 , Rand Rare each independently (C1-C20)alkyl claim 5 , (C2-C20)alkenyl claim 5 , (C2-C20)alkynyl claim 5 , (C3-C7)cycloalkyl claim 5 , (C5-C20)heteroalkyl claim 5 , (C6-C20)aryl claim 5 , (C6-C20)ar(C1-C10)alkyl claim 5 , (C1-C10)alkoxy claim 5 , (C6-C20)aryloxy claim 5 , (C1-C10)alkoxycarbonyl(C1-C20)alkyl claim 5 , or (C1-C20)alkylcarbonyl.7. The ionic liquid of claim 5 , wherein in Chemical Formula 2 claim 5 , Rand Rare each independently (C1-C8)alkyl claim 5 , and Ris (CH) claim 5 , where 1≤n≤12.10. The ionic liquid of claim 9 , wherein in Chemical Formula 6 claim 9 , Rand Rare each independently (C1-C20)alkyl claim 9 , (C2-C20)alkenyl claim 9 , (C2-C20)alkynyl claim 9 , (C3-C7)cycloalkyl claim 9 , (C5-C20)heteroalkyl claim 9 , (C6-C20)aryl claim 9 , (C6-C20)ar(C1-C10)alkyl claim 9 , (C1-C10)alkoxy claim 9 , (C6-C20)aryloxy claim 9 , (C1-C10) ...

Подробнее
Номер записи: 90
29-03-2018 дата публикации

CARBONATE PRODRUGS AND METHODS OF USING THE SAME

Номер: US20180086778A1
Автор: Bley Keith R., Muhammad Naweed
Принадлежит:

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages. 2. A prodrug of wherein the parent drug comprises a hydroxyl group and the prodrug moiety is bound to the moiety of the parent drug at the hydroxyl group.3. A prodrug of claim 1 , provided the parent drug is other than methanol claim 1 , ethanol claim 1 , or phenol.4. A prodrug of claim 1 , wherein the parent drug is a compound selected from the group consisting of acetaminophen claim 1 , hydroquinone claim 1 , metacresol claim 1 , resorcinol claim 1 , parachlorophenol claim 1 , guaiacol claim 1 , phloroglucinol claim 1 , chlorocresol claim 1 , mequinol claim 1 , mercufenol claim 1 , salicylamide claim 1 , chloroxylenol claim 1 , vanillin claim 1 , chlorzoxazone claim 1 , thymol claim 1 , methylparaben claim 1 , phenolsulfonic acid claim 1 , paroxypropione claim 1 , resorcinol claim 1 , brocresine claim 1 , chlorindanol claim 1 , oxyquinoline claim 1 , norepinephrine claim 1 , octopamine claim 1 , dopamine claim 1 , vanillin claim 1 , norfenefrine claim 1 , ethylparaben claim 1 , cloxyquin claim 1 , eugenol claim 1 , hydroxyamphetamine claim 1 , oxidopamine claim 1 , tetroquinone claim 1 , epinephrine claim 1 , hyrnecrornone claim 1 , phenylephrine claim 1 , propofol claim 1 , iodoquinol claim 1 , edrophonium claim 1 , flopropione claim 1 , propylparaben claim 1 , glycol salicylate claim 1 , levonordefrin claim 1 , mephenesin claim 1 , adrenalone claim 1 , chloroxine claim 1 , clioquinol claim 1 , halquinols claim 1 , melizame claim 1 , racepinephrine claim 1 , aminosalicylate claim 1 , epinephrine claim 1 , guaifenesin claim 1 , butylparaben claim ...

Подробнее
Номер записи: 91
31-03-2016 дата публикации

FLAME RETARDANT, FLAME RETARDANT COMPOSITION, AND MOLDED PRODUCT AND MANUFACTURING METHOD THEREOF

Номер: US20160090468A1
Автор: Chen Chiung-Ta, Chien Ming-Yang, Lin Chih-Wei, LIN Liang, Tsay Maw-Der, Tu Kuan-Ju, Wang En-Ching
Принадлежит:

The invention provides a flame retardant, a flame retardant composition, and a molded product and a manufacturing method thereof. The flame retardant has a structure shown in formula (1): 2. The flame retardant of claim 1 , wherein in formula (1) claim 1 , Y claim 1 , Y claim 1 , and Yeach independently represent an oxygen atom; R claim 1 , R claim 1 , and Reach independently represent a Cto Calkyl group claim 1 , a phenyl group claim 1 , or a phenyl group in which an arbitrary hydrogen atom is substituted by an alkyl group or a nitro group.4. A flame retardant composition claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the flame retardant of ; and'}a polymer.5. The flame retardant composition of claim 4 , wherein based on 100 parts by weight of the flame retardant composition claim 4 , a content of the polymer is 65 parts by weight to 90 parts by weight claim 4 , and a content of the flame retardant is greater than 5 parts by weight and less than or equal to 35 parts by weight.6. The flame retardant composition of claim 4 , wherein the polymer comprises an acrylonitrile-butadiene-styrene copolymer claim 4 , thermoplastic polyurethane claim 4 , polyethylene claim 4 , polypropylene claim 4 , polystyrene claim 4 , polymethyl methacrylate claim 4 , polyvinyl chloride claim 4 , nylon claim 4 , polycarbonate claim 4 , polyurethane claim 4 , polyoxymethylene claim 4 , polytetrafluoroethylene claim 4 , polyethylene terephthalate claim 4 , polyisoprene claim 4 , styrene-butadiene rubber claim 4 , butyl rubber claim 4 , polybutadiene rubber claim 4 , chloroprene rubber claim 4 , ethylene propylene diene monomer claim 4 , polyacrylate rubber claim 4 , urethane rubber claim 4 , silicone rubber claim 4 , fluorinated rubber claim 4 , or a combination thereof.7. The flame retardant composition of claim 4 , further comprising an antioxidant claim 4 , a heat stabilizer claim 4 , a UV absorber claim 4 , a light stabilizer claim 4 , a colorant claim 4 , or a ...

Подробнее
Номер записи: 92
21-03-2019 дата публикации

CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

Номер: US20190084908A1
Автор: Dasseux Jean-Louis H., Oniciu Carmen D.
Принадлежит:

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. 157-. (canceled)59. The method claim 58 , wherein each occurrence of Yand Yis independently COORor COOH.60. The method of claim 59 , wherein m is 0.61. The method of claim 59 , wherein m is 1.62. The method of claim 59 , wherein n is 4.63. The method of claim 59 , wherein n is 5.64. The method of claim 59 , wherein X is (CH2)and z is 0.67. The method of claim 58 , the method further comprising administering to a patient in need of such treatment a therapeutically effective amount of a second therapeutic agent.68. The method of claim 67 , wherein the second therapeutic agent is selected from the group consisting of a chemotherapeutic agent claim 67 , an alkylating agent claim 67 , a plant alkaloid claim 67 , a DNA topoisomerase inhibitor claim 67 , a mitomycin claim 67 , an anti-folate claim 67 , a pyrimidine analog claim 67 , a purine analog claim 67 , a hormonal therapy claim 67 , a retinoid claim 67 , a deltoid claim 67 , a vitamin D3 analog ...

Подробнее
Номер записи: 93
30-03-2017 дата публикации

PROCESS FOR REDUCING THE CHLORINE CONTENT OF ORGANOTETRAPHOSPHITES

Номер: US20170088569A1
Автор: DYBALLA Katrin Marie, Franke Robert
Принадлежит: EVONIK DEGUSSA GmbH

Universally usable process for reducing the chlorine content of organotetraphosphites. 2. Process according to claim 1 ,wherein the solution with which the organotetraphosphite is contacted in step a) contains, as well as the at least one solvent and the at least one base, also max. 5% water based on the solvent content.3. Process according to claim 1 ,wherein the at least one base is selected from triethylamine and dimethylaminobutane.4. Process according to claim 1 ,wherein the organotetraphosphite used in process step a) has a chlorine content of 1500 ppm to 100 000 ppm.5. Process according to claim 1 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm.6. Process according to claim 2 ,wherein the at least one base is selected from triethylamine and dimethylaminobutane.7. Process according to claim 2 ,wherein the organotetraphosphite used in process step a) has a chlorine content of 1500 ppm to 100 000 ppm.8. Process according to claim 3 ,wherein the organotetraphosphite used in process step a) has a chlorine content of 1500 ppm to 100 000 ppm.9. Process according to claim 2 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm.10. Process according to claim 3 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm.11. Process according to claim 4 ,wherein the purified organotetraphosphite has a chlorine content of <1000 ppm. The invention relates to a universally usable process for reducing the chlorine content of organotetraphosphites.Organophosphorus compounds have gained considerable industrial significance because of their wide range of use. They are used directly as plasticizers, flame retardants, UV stabilizers or as antioxidants. In addition, they are important intermediates in the production of fungicides, herbicides, insecticides and pharmaceuticals.A specific field of use of the organophosphorus compounds is catalysis:For instance, especially phosphines, phosphites and ...

Подробнее
Номер записи: 94
30-03-2017 дата публикации

METHOD FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING DIMETHYLAMINOBUTANE, TRIETHYLAMINE OR TRIETHANOLAMINE

Номер: US20170088570A1
Автор: DYBALLA Katrin Marie, Franke Robert
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to a universally applicable method for reducing the chlorine content of organomonophosphites using dimethylaminobutane or triethylamine. 2. The process as claimed in claim 1 ,which comprises the additional process step of:{'sub': 5', '10, 'b) introducing the first solution into a second solution comprising a second solvent selected from aromatics, C-C-alkanes, alcohols, acetone, ethyl acetate, acetonitrile, ether, water.'}3. The process as claimed in claim 1 ,wherein the first solution comprises dimethylaminobutane.4. The process as claimed in claim 1 ,wherein the first solvent is selected from: ethyl acetate, anisole, ortho-xylene, toluene, acetone, methanol, ethanol, propanol, isopropanol, acetonitrile, water.5. The process as claimed in claim 1 ,wherein the first solvent is toluene.6. The process as claimed in claim 2 ,{'sub': 5', '10, 'wherein the second solvent is selected from: ethyl acetate, anisole, ortho-xylene, toluene, acetone, methanol, ethanol, propanol, isopropanol, acetonitrile, tetrahydrofuran, diethyl ether, glycol, C-C-alkanes, water.'}7. The process as claimed in claim 2 ,wherein the second solvent is acetonitrile.8. The process as claimed in claim 2 ,wherein the second solution comprises dimethylaminobutane or triethylamine.9. The process as claimed in claim 1 ,wherein the organomonophosphite is dissolved fully in the first solution in process step a).10. The process as claimed in claim 1 ,wherein the purified organomonophosphite has a chlorine content of <200 ppm.11. The process as claimed in claim 2 ,wherein the second solution is brought to a temperature in the range from −10° C. to 80° C. before the first solution is introduced into the second solution in process step b).13. The process as claimed in claim 1 ,wherein{'sup': 1', '2', '3', '4', '5', '6', '7', '8, 'sub': 1', '12', '1', '12', '6', '20', '6', '20, 'R, R, R, R, R, R, R, Rare each independently selected from: —H, —(C-C)-alkyl, —O—(C-C)-alkyl, —O—(C-C)-aryl, —(C ...

Подробнее
Номер записи: 95
30-03-2017 дата публикации

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION

Номер: US20170089911A1
Автор: Ashworth-Sharpe Julia, Bieniarz Christopher, Kelly Brian D., Polaske Nathan
Принадлежит:

Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step. 4. The compound of claim 1 , wherein Ror ZRis a phosphate claim 1 , amide claim 1 , nitro claim 1 , urea claim 1 , sulfate claim 1 , methyl claim 1 , ester claim 1 , beta-lactam claim 1 , sugar claim 1 , or LG and ZRtogether form a phosphodiester.5. The compound of claim 4 , wherein ZRis —OP(O)(OH) claim 4 , NO claim 4 , —NHC(O)R claim 4 , —OC(O)CH claim 4 , —OC(O)CHCH claim 4 , —NHC(O)NH claim 4 , —OS(O)OH claim 4 , OCH claim 4 , or a salt thereof.6. The compound of claim 1 , wherein Ris —(CH)NH— claim 1 , —O(CH)NH— claim 1 , —N(H)C(O)(CH)NH— claim 1 , —C(O)N(H)(CH)NH— claim 1 , —(CH)O— claim 1 , —O(CH)O— claim 1 , —O(CHCHO)— claim 1 , —N(H)C(O)(CH)O— claim 1 , —C(O)N(H)(CH)O— claim 1 , —C(O)N(H)(CHCHO)— claim 1 , —(CH)S— claim 1 , —O(CH)S— claim 1 , —N(H)C(O)(CH)S— claim 1 , —C(O)N(H)(CH)S— claim 1 , —(CH)NH— claim 1 , —C(O)N(H)(CHCHO)CHCHNH claim 1 , —C(O)(CHCHO)CHCHNH— claim 1 , —C(O)N(H)(CH)NHC(O)CH(CH)(CH)NH— or —N(H)(CH)NH— claim 1 , where each n independently is 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 claim 1 , 9 claim 1 , 10 claim 1 , 11 or 12.7. The compound of claim 1 , wherein Ris a chromogen claim 1 , a fluorophore claim 1 , a luminophore claim 1 , a ...

Подробнее
Номер записи: 96
19-06-2014 дата публикации

CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

Номер: US20140171394A1
Автор: Duarte Carolina, Koumbis Alexandros, Lehn Jean-Marie, Nicolau Claude, Pothukanuri Srinivasu
Принадлежит:

The present invention is directed to polyphosphorylated and pyrophosphate derivatives of cyclitols. More particularly, the invention relates to polyphosphorylated and pyrophosphate derivatives of inositols. The invention also relates to compositions of the polyphosphorylated and pyrophosphate derivatives of inositol and other similar, more lipophilic derivatives, and their use as allosteric effectors, cell-signaling molecule analogs, and therapeutic agents. 131.-. (canceled)32. A composition comprising a pyrophosphate inositol which reduces hemoglobin's oxygen affinity , wherein:the pyrophosphate is an internal pyrophosphate;the inositol is cis-inositol, epi-inositol, allo-inositol, muco-inositol, neo-inositol, scyllo-inositol, (+) chiro-inositol, or (−) chiro-inositol, and wherein the pyrophosphate inositol is monopyrophosphate, bispyrophosphate, or trispyrophosphate; andthe pyrophosphate inositol comprises a derivatized hydroxyl selected from alkoxy (—OR) or acyloxy (—OCOR),where R is selected from alkyl, aryl, acyl, aralkyl, alkenyl, alkynyl, heterocyclyl, polycyclyl, carbocycle, amino, acylamino, amido, alkylthio, sulfonate, alkoxyl, or sulfoxido, or a salt thereof.33. The composition of claim 32 , wherein the pyrophosphate inositol is complexed with a cation to form a salt claim 32 , and wherein the cation is an alkali metal cation claim 32 , an alkaline metal cation claim 32 , an ammonium claim 32 , or an organic cation.34. The composition of claim 32 , wherein R is a lower alkyl.35. The composition of claim 34 , where R is methyl.36. The composition of claim 32 , wherein the inositol is scyllo-inositol.37. The composition of claim 32 , wherein the inositol is monopyrophosphate.38. The composition of claim 32 , wherein the inositol is bispyrophosphate.39. A pharmaceutical composition claim 32 , comprising a pyrophosphate inositol wherein:the pyrophosphate is an internal pyrophosphate;the inositol is cis-inositol, epi-inositol, allo-inositol, muco-inositol, neo ...

Подробнее
Номер записи: 97
28-03-2019 дата публикации

LECITHIN-BASED SPRAY ADJUVANT CONTAINING ORGANOSILICON WETTING AGENTS

Номер: US20190090489A1
Автор: Mukherjee Narayan, Naue Jeferson A., Policello George A.
Принадлежит:

An adjuvant composition contains lecithin and an organosilicon surfactant as defined herein. 1. An adjuvant composition comprising:a) lecithin; and, {'br': None, 'sup': '1', 'sub': 3', '2, 'R—Si(CH)—Z'}, 'b) an organosilicon surfactant of general formula (I)wherein:{'sup': '1', 'Ris a branched monovalent hydrocarbon group of from 5 to 8 carbon atoms containing at least two methyl groups;'}{'sup': 2', '3, 'Z is Ror R;'}{'sup': 2', '4', '4, 'sub': 2', '2', '2', '2', '4', 'a', '3', '6', 'b', '4', '8', 'c, 'Ris CHCHCH—O—(CH—O)(CHO)(CHO)—Rin which Ris hydrogen, a linear or branched monovalent hydrocarbon group of from 1 to about 4 carbon atoms or an acyl group, subscript a is from 1 to about 20, subscript b is from 0 to about 19, subscript c is from 0 to about 19 and the sum of subscripts a, b and c is from 1 to about 20; and,'}{'sup': 3', '+', '5', '−', '5', '−, 'sub': 2', '2', '2', '2', '3', '2, 'Ris —CHCHCH—O—CH(OH)CH—N(CH)—R[X] in which Ris a linear or branched hydrocarbon group of from 1 to about 4 carbon atoms or an acetyl group and X is a saturated or unsaturated carboxylate anion of from 2 to about 22 carbon atoms containing 0 to 2 hydroxyl groups.'}2. The adjuvant composition of wherein the lecithin component (a) contains from 10 to 70 weight percent lecithin as phosphalidylcholine with the balance being selected from phosphatidylethanolamine claim 1 , phosphalidylinositol claim 1 , phosphatidic acid claim 1 , glycolipids claim 1 , complexed sugars and triglycerides claim 1 , having a hydrophilic-lipophilic balance between 2 and 15.3. The adjuvant composition of wherein the lecithin component (a) has an average acetone insoluble (AI) content of more than 60 weight percent.4. The adjuvant composition of wherein the lecithin component (a) has an average acetone insoluble (AI) content of more than 60 weight percent.6. The adjuvant composition of wherein Rcontains from 2 to 4 methyl groups claim 5 , CRRRis selected from the group consisting of HC— claim 5 , (HC)CH— ...

Подробнее
Номер записи: 98
07-04-2016 дата публикации

Phosphate Ester Dispersion Promoting Agent and Dispersion Comprising the Same

Номер: US20160096965A1
Автор: Chen Xiahu, Duan Gang, Lai Hua, Lin Kuai, Wang Jin, Wen Jinsong, Zhang Yinchao
Принадлежит: Valspar Sourcing, Inc.

This disclosure is directed to a phosphate ester dispersion promoting agent and process for the preparation thereof. The present disclosure also relates to a dispersion of a particulate solid comprising the phosphate ester dispersion promoting agent and use of the phosphate ester dispersion promoting agent for dispersing a particulate solid. The phosphate ester has the structure of formula (I): 2. The dispersion according to claim 1 , wherein the polyester residue R has a number-average molecular weight in the range of 200 to 1500 g/mol.3. The dispersion according to claim 1 , wherein the ratio by number of the ether oxygen atom if present to carboxylate ester groups —COO— in the skeleton is in the range of 1:2 to 3:1.7. The dispersion according to claim 5 , wherein the phosphating agent is selected from the group consisting of phosphorus oxychloride claim 5 , phosphorus pentoxide claim 5 , polyphosphoric acid claim 5 , pyrophosphoric acid and combination thereof.8. The dispersion according to claim 1 , wherein the particulate solid comprises pigments or fillers.9. The dispersion according to claim 8 , wherein the particulate solid comprises metals claim 8 , alloys claim 8 , metal oxides claim 8 , metal salts claim 8 , silicon dioxide claim 8 , or silicates.10. The dispersion according to claim 9 , wherein the particulate solid is titanium dioxide in the form of powder.11. The dispersion according to claim 1 , wherein the dispersing medium comprises polar organic liquids claim 1 , polar resins claim 1 , or non-polar organic liquids.12. The dispersion according to claim 1 , comprising claim 1 , relative to the total weight of the dispersion of the particulate solid claim 1 ,5 to 3.0% by weight of the phosphate ester as a dispersion promoting agent;40 to 80% by weight of the particulate solid;20 to 40% by weight of the dispersing medium; and0 to 10% by weight of one or more additional additives.14. The phosphate ester used as a dispersion promoting agent according to ...

Подробнее
Номер записи: 99
05-04-2018 дата публикации

Method for Purification of Lecithin

Номер: US20180094008A1
Автор: Jos VAN DENDEREN, Robert Stevens
Принадлежит: Cargill Inc

The present invention relates to a method for the purification of lecithin, comprising the steps of (a) mixing lecithin with active carbon to form a dispersion; then (b) mixing an organic solvent into the dispersion; then (c) separating the active carbon and contaminants from the lecithin preferably through gravitational forces. The invention further relates to a lecithin substantially free of contaminants, and a food or feed product comprising said lecithin.

Подробнее
Номер записи: 100